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ABSTRACT 
Continued pressure to reduce costs and manage healthcare delivery in risk-based reimbursement 
environments, has, internationally, resulted in hospitals adopting different methods to manage 
pharmaceutical and surgical consumable products. An initial review of systems of management of 
these products showed that the trend is to manage them separately. Pharmaceutical products are 
managed using dedicated resources and structures in each hospital, which may be difficult to 
establish and sustain in smaller, non-academic hospitals. Amongst other factors, the absence of a 
classification system and a lack of utilisation information hindered the development of management 
systems for surgical consumable products. In addition, traditional materials management processes 
applied to these products, often do not adequately address the impact that these products have on 
clinical care. In this study, the decision was made to develop an integrated system for both 
pharmaceutical and surgical consumable products and to adopt a systems approach in which all 
hospitals in the group were included as a single system. 
The study was multi-methodological with the design being contextual and qualitative and the 
research strategy, exploratory and descriptive. A multi-phased, action research approach was used, 
comprising of three (3) cycles, two (2) in which the integrated system was developed and enhanced 
and a third in which it was independently tested in 19 newly acquired hospitals. 
The result of the three (3) cycles was an implemented integrated system across 43 acute-care 
hospitals in the group comprising six (6) processes namely: a product selection process, 
information technology (IT) support system, a hospital implementation process, measurement and 
management tools, pharmacy capability and a supplier strategy and interface process. These 
processes included several key unique features, such as one (1) product selection team for all 
hospitals, a surgical classification system based on functional therapeutic uses, a single IT system 
and utilisation review capability for all products, extending the role of pharmacy departments in 
hospitals to include the management of surgical consumable products and an integrated quality 
assessment process for both types of products. By the end of the three (3) cycles (September 
1999), the product selection process covered 66,5% of value of product spend, the percentage 
reduction in the number of products used was 68% and the value of products purchased that 
complied with specified products and suppliers was 90%. Ongoing and further application showed 
that the integrated system could be sustained in existing hospitals, applied to a further four (4) 
newly acquired hospitals and expanded to include specialised pharmaceutical and surgical 
consumable products in cardiac catheterisation laboratories. By September 2003, the total spend 
on pharmaceutical and surgical consumable products had reached R1,7 billion. The product 
selection process covered 67,6% of total spend, the compliance value reached 95% and there were 
additional financial improvements realised. 
Following a further literature review, limitations and improvements to the approach were identified 
and further adaptations were added as concepts in the graphic representation of system. One (1) of 
these was to show the integrated system as an open system. The second adaptation highlighted 
the systems-based input-process-outcomes feedback concept that is critical to continuous 
improvement of the system. In the final progression, a systems approach to strategic planning and 
management was incorporated in order to provide a structured approach for adapting to the rapid 
and ongoing changes in healthcare and aligning the system of management of pharmaceutical and 
surgical consumables to the overall business strategy. 
Overall, this research study succeeded in bringing new perspectives and an innovative approach to 
the management of pharmaceutical and surgical consumable products by developing and 
implementing an integrated system for both products, establishing essential processes with key 
unique features and tools, and the application of a systems thinking approach. Four (4) areas of 
further research are suggested, namely testing the integrated system in other contexts, improved 
methods of measurement of quality of care, extension to other areas of healthcare and use of the 
systems approach in other areas of the business. 
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Afrox Pharmacy Management Services (see also under HHD). 
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Chief Financial Officer. 
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frequency that a drug must be taken in 24 hours. 
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Per diem 
This is a financial term used in the healthcare environment meaning that a fixed 
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PREFACE 
This submission covers the innovation report for the study. 
The submission is divided into nine (9) chapters, namely: 
" Chapter 1 describes the links between the business objectives and the 
research aims of the study and outlines the review of international systems of 
management of pharmaceutical and surgical consumable products; 
" In Chapter 2, the research objectives, design and methods are described; 
" Chapter 3 provides an overview of the three (3) action research cycles of the 
study in order to determine what is needed to develop and maintain an 
integrated system for the management of pharmaceutical and surgical 
consumable products; 
" The progression of the integrated system over the action research cycles is 
described through graphic representations in Chapter 4; 
" In Chapter 5, the integrated system is compared to international systems 
through further literature examination; 
" Applications of the integrated system since the three (3) action research cycles 
are described in Chapter 6; 
" Reflections of the business objectives are covered in Chapter 7; 
"A further progression of the integrated system is described in Chapter 8 and 
benefits discussed; and 
" In the final chapter the innovations of the study are summarised and focus 
areas for further research highlighted. 
xv 
CHAPTER I 
CONNECTING RESEARCH AND BUSINESS PRACTICE 
1.1 Introduction 
1.2 Definitions 
1.3 Rationale for the 
study in AHL 
1.4 International and 
national perspective 
1.5 The concept of an 
integrated system 
1.6 Application of a 
systems approach 
1.7 Concept map of the 
study 
1.1 INTRODUCTION 
11 IGllil IV[ 1 LV VJ. U). 
Transformational processes in organi- 
sations are often initiated by some force 
that alerts people to the need for change. 
Examples of these force factors include 
underperformance, decreased product- 
ivity or changing market conditions 
CIS+r. ktr ')nnQ"Q\ 
In this study, the force factor that initiated the need for change was Afrox 
Healthcare's (AHL) acquisition of the six (6) hospitals in the Port Elizabeth 
Medical Group (PEMG) in 1998. This acquisition provided a critical mass of 25 
hospitals, which made AHL a significant player in the private healthcare industry. 
The thinking in the organisation began to change from running a number of 
single entity hospitals to the question of " ... 
how do we make the whole greater 
than the sum of its parts? " The consolidation of hospitals into a larger group had 
the potential for delivering significant economic benefits to the organisation 
through the realisation of opportunities for synergy and leverage. 
Independent studies have shown that most change initiatives and reengineering 
projects fail (Armenakis & Harris, 2001: 169). Failure rates have been shown to 
be around 70% in studies of reengineering, and in studies of corporate 
transformations, up to 50% do not survive the initial phase (Champy, 1995: 29 
and Kotter, 1995: 59). Furthermore, studies of merged or acquired companies 
1 
showed that merger objectives were only met half of the time, and synergy and 
leverage objectives relating to cost reduction were the least achieved (Feldman 
& Spratt, 1999: 9). 
In approaching the opportunities and problems presented, rather than use a 
conventional reengineering approach, I chose to connect business practice and 
research. From a business perspective, my aim was to achieve the main 
business objective of leverage. As research practitioner, I set out to develop new 
perspectives and bring new thinking to the opportunity/problems and thereby 
contribute to wider learning. The approach offered the challenge of using the 
new perspectives and thinking to create new ideas, act on them and test them 
out in practice. 
To meet this challenge I used an action research paradigm that included a 
participative collaborative process, as well as independent critical review and 
conceptualisation by the researcher (myself). Details of the research 
methodology will be provided in Chapter 2. 
1.2 DEFINITIONS 
Within the context of exploring opportunities of leverage for the larger group, the 
focus of this study was to explore opportunities relating to the management of 
pharmaceutical and surgical consumable products. 
Pharmaceutical products, also referred to as drugs or medicinal drugs, are 
defined as any chemical compound that may be used on or administered to 
humans or animals as an aid in the diagnosis, treatment or prevention of 
disease or other abnormal condition (Dorland's Illustrated Medical Dictionary, 
1994). Examples include antibiotics and pain medicines (analgesics). 
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Surgical consumable products, also known as medical consumables or 
medical/surgical devices, are defined in this study as products other than 
pharmaceutical products or medicines that may be used on humans or animals 
as an aid in the diagnosis, treatment, monitoring or prevention of a disease or 
other abnormal condition (UK Medical Devices Agency (MDA), 2003: 5). Surgical 
consumable products do not achieve their primary intended purpose through 
chemical action within the body of man or animals, nor are they dependent upon 
being metabolised for the achievement of their primary intended purpose (U. S. 
Food and Drug Administration, 1998: 1). Examples include bandages, wound 
closure products, prosthetics, surgical gloves and catheters. Instruments, 
apparatus and machines were not included in this study as surgical consumable 
products, since they are standard fixed items rather than consumables, i. e. used 
up during the course of diagnosis or treatment of a patient. 
In keeping with the combined business and research approach, I will firstly 
present a summary of the rationale for the study in AHL. As background to the 
research aim, I will then present an overview of the international and national 
perspective of the management of these products. Key differences in my 
approach compared to other studies will be highlighted and discussed. Finally I 
will show the combined business and research approach in a concept map of 
the study. 
1.3 RATIONALE/MOTIVATION FOR THE STUDY IN AHL 
AHL, listed on the Johannesburg Stock Exchange (JSE) as Ahealth, is a leading 
provider of private healthcare in Southern Africa. The group holds approximately 
34% of the South African private healthcare market through a diverse portfolio of 
healthcare-related services and investments. The acute care hospital division, 
which accounts for almost 80% of turnover (Jankelow, 2000: 5), forms the core of 
the business and is the focus of the study. (The abbreviation 'AHL' will from here 
3 
on refer to the acute care hospital division only). The said division began with 
three (3) hospitals in 1983 and through a series of acquisitions has progressed 
to over 60 hospitals to date, of which 18 are same-day surgical centres linked to 
hospitals (see Figure 1.1). 
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Figure 1.1: Growth in number of acute care hospitals in AHL: 1983 - 2004 
In June 1997 I was appointed as managing director (MD) of the pharmacy 
management company of AHL, known as Home and Hospital Dispensaries 
(HHD) Pty Ltd. An analysis of hospital turnover at the end of 1997 indicated that 
pharmaceuticals and surgical consumables made up almost 45% of total group 
hospital turnover. The total purchases for these products amounted to R 236 
million, and of that R 124 million and R 112 million were spent on 
pharmaceuticals and surgical consumables respectively. There were 28,000 
individual products within the two (2) categories of which approximately 6000 
were pharmaceuticals and 22,000 were surgical consumables. This ratio was 
duplicated in individual hospitals where approximately 10,000 to 15,000 different 
4 
products were used, depending on their size and number of medical and 
surgical specialties offered. 
In addition to the opportunity to leverage the total group usage, there were 
several external changes (driving forces) that directly influenced my decision to 
proceed with this study, namely: 
" Consistent with international trends, continued price increases in terms of 
pharmaceuticals and surgical consumables, which were significantly higher 
than the consumer price index (CPI), were experienced during the late 
1990's (Van der Merwe, 1998: 33; Bisseker, 1999: 98; De Bruin, 2000: 24 and 
Bridge, 2001: 79); 
" Tariff increases by medical schemes were not keeping up with inflation in the 
industry (Joubert, 1997: 106), resulting in overall pressure on margins in AHL; 
" New legislation aimed at reducing the cost of medicines. The new legislation 
carried the threat of stricter centralised control over the private market for 
pharmaceuticals (Van den Heever, 1999: 167); and 
" Medical insurance companies (referred to as "funders" in SA) had begun to 
introduce new reimbursement systems such as fixed fees (fixed fee per 
procedure or per diagnosis) or per diem fees (a set fee per day regardless, of 
the procedure) that placed a risk on hospital providers, both with regard to 
price and the utilisation of pharmaceuticals and surgical consumables (Tuft 
1997: 31 and Van der Merwe, 1998: 34). 
In AHL, an important medical aid moved its hospital reimbursement to a per 
diem method in January 1998. This represented 5% of total group turnover at 
the time. By 2003, per diem and fixed fees accounted for 40% of turnover (Afrox 
Healthcare, 2003c) and is expected to reach over 70% in 2005 (AHL, 2004). 
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Arising from the question of how to make the whole greater than the sum of its 
parts, a strategic planning workshop was held to review current practices in the 
management of pharmaceuticals and surgical consumables and set a strategy 
for the way forward. 
Arising from the internal and external factors described, the following actions 
were taken: 
" Due to the total value of pharmaceutical and surgical consumable products 
and their combined impact on costs in per diem and fixed fee systems, the 
management system developed would need to integrate both types of 
products. Further discussion of this decision will be presented in section 1.4 
of this chapter; 
" AHL withdrew from the pharmaceutical buying group known as United 
Hospital Supply Corporation (UHSC), and brought both pharmaceutical and 
surgical consumable procurement under the umbrella of its pharmacy 
management company (HHD). It was believed that rationalisation of both 
suppliers and products would best be achieved through direct contact with 
suppliers and would allow AHL to leverage more successfully. 
" The pharmacy management company and procurement departments were 
merged and re-engineered to provide capacity to develop and deliver a 
strategy to manage pharmaceutical and surgical consumables across all 
hospitals. 
As MD of the newly combined HHD, I redefined the role of the company, and 
proceeded to develop systems and processes that met both professional 
standards and business and financial goals in relation to pharmaceutical and 
surgical consumable products and pharmacy services across the group. The 
company was later renamed as Afrox Pharmacy Management Services (APMS). 
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The need for dedicated resources for the project was recognised and 
consequently a project team, with myself as leader, was established and the 
following project goals were determined: 
" To identify synergy opportunities and leverage the total group spend in 
pharmaceutical and surgical consumable products; 
" To develop the capability of managing product selection and usage for both 
types of products by pharmacists, nurses and doctors across all AHL 
hospitals; and 
" To manage and support the implementation of this process to ensure that 
quality and optimal therapeutic outcomes, meet financial targets and 
maximise leverage opportunities. 
As research practitioner, I conducted a literature review, which served as a 
baseline and background for the study in order to determine the research aim. 
1.4 INTERNATIONAL AND NATIONAL PERSPECTIVE 
This section describes an overview of the findings of the literature review 
conducted at the start of the study (Submission 1) and provides a more general 
overview of management systems used for pharmaceutical and surgical 
consumable products. The second literature (Submission 3) was a specific 
comparison between the developed system at the end of the action research 
cycles and international developments. Further discussion of this review will be 
presented in Chapter 5. 
Since the international and national trend was for hospitals to manage 
pharmaceutical and surgical consumables separately, I will discuss the 
management of each of these types of products in turn. 
7 
1.4.1 Pharmaceutical product management 
Increasing pressures on pharmaceutical product expenditures, as well as the 
variation and proliferation of products, resulted in hospitals adopting different 
methods or a combination thereof to manage rational drug use (Martinez 
Bengoechea et at., 1997: 89; Hogerzeil, 1995: 2 and ASHP, 1983: 1384). The 
trend identified in the review of international countries, i. e. United States of 
America (USA), United Kingdom (UK), the Netherlands, Germany and Australia, 
indicated that pharmaceutical product management occurred through hospital 
formularies, pharmacy and therapeutic committees (PTC's) and drug utilisation 
reviews (DUR's) for each individual hospital (Crawford, et al., 1993: 1371; 
Hogerzeil, 1995: 2; Fijn, et al., 1999: 76 and Thurmann, et at., 1997: 434). As a 
result, committee structures and resources were replicated in each hospital and 
individual formularies developed for each. Smaller, non-academic hospitals were 
often not able to maintain these structures and resources (Thurmann, et at., 
1997: 434). 
In South Africa (SA), the only published survey of hospital pharmaceutical 
services indicated that while 46% of all hospitals and 10% of individual private 
hospitals reported using a formulary of some kind, in most cases this referred to 
a list of drugs available, which is a formulary in its most limited sense (Summers, 
1991: 70). In 1998, a number of formularies were launched for general 
practitioners in the private healthcare community in SA. However, the use of 
these formularies was described as " ... in a state of transition ... " and little work 
had been done to measure their effectiveness (Watson, 1999: 134). 
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1.4.2 Management of surgical consumable products 
Internationally and nationally, the management of surgical consumable products 
(in the public sector) was through the general materials management and 
hospital procurement departments. Systems, such as those used for 
pharmaceutical products, were not used for rationalising surgical consumable 
products, despite increasing costs and new regulations to govern safety and 
efficacy of these products (Kachieng'a & Boonzaier, 1999: 151 and Andrews, 
2001: 19). International data indicated that the inventory of surgical consumable 
supplies may cover 10,000 to 15,000 items in a hospital and is estimated to 
account for between 25% and 30% of a hospital's budget (Willock & Motley, 
1998: 46; Eskew, 2002: 24 and UK Medical Devices Agency, 2003: 1). 
In SA, the purchase of surgical consumables was done through buying 
consortiums or a tender process with little information available to assess 
efficacy, cost-benefit and cost-effectiveness (Kachieng'a & Boonzaier, 1999: 
152). 
1.4.3 Differences highlighted from the international and national 
perspective 
The review of the international and national perspective showed that whilst I 
could use concepts from the systems of management of pharmaceutical 
products in hospitals, the approach to the study contrasted with existing "best- 
practice" in the following two key areas: 
" The decision to develop a system of management that integrated the two (2) 
categories of products, namely pharmaceutical and surgical consumable 
products; and 
" The application of the systems thinking approach. 
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I will briefly discuss these concepts as further background to the study. A more 
detailed discussion of these differences will be provided in Chapter 5. 
1.5 THE CONCEPT OF AN INTEGRATED SYSTEM 
As stated in section 1.4.3, the decision to develop an integrated system was the 
first of two (2) key differences highlighted from the initial review of international 
systems of management for pharmaceutical and surgical consumable products. 
The following four definitions of "integrate" were used in the study: 
0"... to form into one whole, to join with something else, to make part of a 
larger unit... " (Dictionary. com, 2004); 
""... to combine two or more things in order to become more effective ... " 
(Cambridge International Dictionary of English, 2004); 
0 "... to bring together and blend into a whole, to unite with something else to 
create a whole ... " (Wordsmyth English Dictionary, 2004); and 
0"... to form, co-ordinate, or blend into a functioning or unified whole ... " 
(Merriam-Webster Online Dictionary, 2004). 
In the context of this study the concept of an "integrated" system was applied as 
follows: 
9 Combining the management of pharmaceutical and surgical consumable 
products into one (1) system; 
" Identifying and bringing together different processes into a whole, i. e. one (1) 
management system; and 
" Combining and co-ordinating all hospitals in the group into one (1) "unified 
whole" - using the systems thinking approach. 
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The application of each of these concepts will be described in the summary of 
the three (3) action research cycles in Chapter 3 and reviewed further in Chapter 
5. 
1.6 APPLICATION OF A SYSTEMS APPROACH 
The second key difference highlighted from the international review was the 
decision to use a systems approach to the study. 
Senge (1990: 12) stated that sustaining any profound change requires a 
fundamental shift in thinking in which there can be true commitment to a shared 
picture of the future. However, he added that "... vision without systems thinking 
ends up painting lovely pictures of the future with no deep understanding of the 
forces that must be mastered to move from here to there ... 
". The systems 
thinking approach was an important aspect of the conceptualisation of the 
integrated system, and a key new perspective that I introduced as the research 
practitioner. 
The application of the systems approach provided a new conceptual model, or 
mental image of the organisation and introduced the concept of processes in the 
study and highlighted the need for interaction within and between subsystems. 
A summary of the key ideas related to the systems approach is presented in 
Table 1.1, and compared to the international approach in public and private 
hospitals (representing existing knowledge). Justification of each of the 
differences was provided in Submission 3 of the study based on a detailed 
review of the systems thinking literature. 
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Table 1.1: Comparison of the systems approach to the international 
approach applied to the management of pharmaceutical and 
surgical consumable products 
APPROACH WITHIN THE INTEGRATED INTERNATIONALLY AS DERIVED FROM 
SYSTEM. THE LITERATURE REVIEW 
(Detailed discussion of each of these (Detailed discussions with references to 
applications were described in Chapter 4 of substantiate these statements are provided in 
The development of a system which first 
views all hospitals in AHL as a whole and 
results in a process driven approach that 
focuses on the overall purpose of synergy 
realisation. 
The approach that views a hospital as a 
system recognises the interrelatedness of 
different departments and the impact and 
role they play in the management of product 
usage. Boundaries are integrated and 
collaborative. 
Hospitals within a group or a region are 
predominantly viewed as individual units and 
systems of management are duplicated in each 
unit. This results in an activity or problem 
focused and narrow view. 
There is increasing recognition of the need to 
view a hospital as a system, however the 
application of this concept has not generally 
been applied in the approach to the 
management of total product usage. Separate 
activities are initiated in different departments 
resulting in a fragmented approach and turf 
The systems approach identified the 
interrelatedness of the management of 
pharmaceutical and surgical consumable 
products and a mind shift that resulted in the 
development of the integrated system for the 
management of both types of products. 
The adoption of the concept of leverage 
within systems thinking. The application of 
systems thinking to leverage product usage 
across the total group of hospitals. The 
ability to leverage resources and 
infrastructure across all hospitals and across 
both pharmaceutical and surgical 
The use of the systems input-feedback- 
outcomes approach provides a continuous 
feedback mechanism and facilitates the 
availability of integrated information across 
the system and subsystems. 
Pharmaceutical management systems exist in 
isolation from the management of surgical 
consumable products despite increasing 
recognition of the similarities of systems 
required for their management. 
The individual hospital and individual 
departmental (silo) approach limits 
opportunities for leverage. There is duplication 
of management systems in each hospital and 
within hospitals, resulting in no leverage of 
resources and infrastructure across 
pharmaceutical and surgical consumable 
The independent approach in separate 
hospitals and departments provides a limited 
view. There is poor information flow from one 
(1) hospital and/or department to the next. 
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APPLICATIONS OF THE SYSTEMS GENERAL APPROACH IN HOSPITALS 
APPROACH WITHIN THE INTEGRATED INTERNATIONALLY AS DERIVED FROM 
SYSTEM. THE LITERATURE REVIEW 
(Detailed discussion of each of these (Detailed discussions with references to 
applications were described in Chapter 4 of substantiate these statements are provided in 
Submission 3) Chapter 4 of Submission 3) 
Recognition that the macro system (AHL Follow a problem-oriented, analytical approach 
group of hospitals) and the subsystems in individual hospitals and departments. Try to 
(hospitals, departments, etc. ) are open control individual subsystems as closed 
systems that are impacted by and impact on systems. 
the environment, including funders, 
suppliers, the private healthcare sector, 
communities, etc. (Cycle 2 and Submission 
3 
Most business are not process-oriented but rather focused on tasks, jobs, 
people and structure (Hammer & Champy, 1993: 35). The goal to create 
leverage and realise synergies from a systems approach provided an overall 
purpose and also drove a process approach to the study rather than a traditional 
analysis approach to the problem/opportunity. The word "analysis" comes from 
the root meaning "to break into constituent parts" (Aronson, 1996: 1). By using 
systems thinking, I was able to focus on the whole and on the feedback 
relationships between what was being studied and the other parts of the system 
rather than focus on tasks or individual components. 
The benefits derived from and limitations of the systems thinking approach will 
be discussed further in Chapter 5. 
1.7 CONCEPT MAP FOR THE STUDY 
The study followed three (3) key phases as shown in the concept map in Figure 
1.2, namely: 
" An initial literature review provided the background to the study and formed 
the basis of the establishment of the research aim (Chapter 2); 
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" This was followed by three (3) action research cycles of reflecting, planning, 
acting and observing. At the end of each cycle, I presented the outcomes 
from a business perspective (Chapter 3). As the researcher, I also reflected 
further on each cycle and presented the results in terms of the broader 
research aim (Chapter 4); and 
" In the third phase of the study, I conducted a second detailed literature 
review to justify and understand the limitations of the developed system, 
highlight differences from the international approach and identify 
improvements and additions to the system (Chapter 5). 
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In this submission, which constitutes the Innovation Report, I will subsequently: 
" Describe the applications and outcomes of the integrated system after the 
action research cycles (Chapter 6); 
" Reflect on the achievement of the business objectives (Chapter 7); 
" Further progress the conceptualisation of the integrated system (Chapter 8). 
Finally, I will present the conclusions of the study and focus areas for further 
research (Chapter 9). 
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CHAPTER 2 
RESEARCH OBJECTIVES, DESIGN AND METHODS 
2.1 Introduction 
2.2 Research questions 
2.3 Aims and objectives of 
the study 
2.4 Change management 
2.5 Research paradigm 
2.6 Research design and 
research methods 
2.7 Trustworthiness of the 
study 
2.8 Summary 
2.1 INTRODUCTION 
In this chapter I will present the research 
questions, aim and objectives of the 
study, followed by an explanation of the 
research paradigm and a summary of the 
research design and methods used in the 
study. 
I formulated the research questions, aim and objectives of the study from the 
review of the business objectives and a reflection on international and national 
perspectives as described in Chapter 1. 
The study was a reflective study with multi-phased (arranged in cycles) and 
multi-methodological designs. The generic paradigm used throughout the study 
was that of action research, with the design being contextual and qualitative and 
the research strategy exploratory and descriptive. Because of the emphasis on 
implementing the integrated system at the same time as it being developed, I 
also used change management methodologies as a core methodology related to 
the business change, which I incorporated into action research (AR). 
2.2 RESEARCH QUESTIONS 
I formulated the following concepts that served as the main research question of 
the study: 
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What will an integrated system for the management of pharmaceutical and 
surgical consumable products across the group of hospitals in AHL 
consist of? 
In order to develop and implement the system, I conducted the study through 
three (3) action research cycles. The rationale for this methodology will be 
discussed later in this chapter. 
As the study was conducted using action research, the sub-questions are 
presented within the three (3) action research cycles with a concluding final 
question. 
Cycle 1: 
" What processes and information technology (IT) support will contribute to the 
development of a system for the management of pharmaceutical and 
surgical consumable products in AHL? 
" How would the developed system perform when implemented across the 
hospitals in the group? 
Cycle 2: 
" What support elements will address the gaps identified during the 
implementation phase of cycle 1? 
" How will the adapted system perform in the existing AHL hospitals? 
Cycle 3: 
. What will be the results of implementing the adapted system in 19 newly 
acquired hospitals? 
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Concluding question: 
" Will the existing knowledge framework add to the development of a system 
for the management of pharmaceutical and surgical consumable products in 
AHL? 
2.3 AIM AND OBJECTIVES OF THE STUDY 
The overall aim of the study was the development of an integrated system for 
the management of pharmaceutical and surgical consumable products across 
the group of acute care hospitals in AHL. 
The objectives of the study were respectively formulated within the three (3) 
action research cycles as follows: 
Cycle 1: 
" To explore what processes and procedures will contribute to a successful 
product selection method for pharmaceuticals and surgical consumables; 
" To develop the information technology (IT) support that would be required as 
a component of the integrated system for the management of pharmaceutical 
and surgical consumable products; and 
" To implement and evaluate the developed system across the hospitals in 
AHL. 
Cycle 2: 
" To identify the gaps resulting from the implementation of the system in Cycle 
1; 
" To develop support elements for the identified gaps; and 
" To verify the adjustments by retesting the system in AHL hospitals. 
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Cycle 3: 
" To implement and evaluate the improved and integrated system in 19 newly 
acquired hospitals in AHL. 
Concluding objectives: 
" To examine the processes and outcomes of the action research cycles 
against the literature; 
" To assimilate the concepts derived from Cycles 1,2 and 3 and the literature 
examination in order to further conceptualise the integrated system; and 
" To present the justification, limitations and recommendations of the study. 
2.4 CHANGE MANAGEMENT 
The ODR MOC® methodology was the main change management methodology 
used for the business change and included a set of structured procedures, 
diagnostic tools and comprehensive techniques that have been researched and 
formulated by ODR® Inc. (Conner, 1995). Details of the methodology and the 
specific tools used during data gathering were described in detail in the relevant 
cycle where such were applied. 
Two (2) other change management concepts, as presented by Zuber-Skerritt 
(1996: 96), were utilised in the study, namely: 
" Lewin's three-stage model of organisational change (unfreeze, move and 
refreeze); and 
" Change management steps by Beer et al. were incorporated into the 
research methods. 
The incorporation of these into the adapted research paradigm is illustrated in 
Figure 2.2 of this chapter. 
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2.5 RESEARCH PARADIGM 
I adapted and developed an action research paradigm, based on the 
descriptions of Whyte (1995), Dick (2000) and Zuber-Skerritt (1995,1996,2000 
and 2001), and also included Karlsen's action research model (Karlsen, 1991), 
which will now be discussed. 
2.5.1 Action research 
The generic paradigm used throughout the study is action research, and was 
firstly chosen because emphasis is on the implementation of change while at the 
same time developing a system that is replicable in the context of the group. 
Action research is a strategy that brings about change through action, 
developing and improving practice and at the same time, generating and testing 
theory (Dick, 2000: 67 and Greenwood, 1994: 13). 
This choice was secondly influenced by the decision to conduct the study across 
all AHL hospitals involving multiple levels and disciplines of staff. Action 
research is a dual commitment to studying a system and concurrently 
collaborating with members of the system on what is mutually regarded as a 
desirable direction (Zuber-Skerritt, 2001: 3). 
To accomplish this goal, active collaboration from both the researcher and 
participants is required, and thus the importance of co-learning as a primary 
aspect of action research is emphasised (O'Brien, 1998: 2). In this study, I 
collaborated with members of the project team in each cycle, and at various 
stages with consultative forums consisting of members of staff from the 
hospitals. 
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The cornerstone of action research is based on the concept that knowledge is 
derived from practice, and that practice informed by knowledge is an ongoing 
process (O'Brien, 1998: 6). The following five (5) steps, as suggested by O'Brien 
(1998: 6) were used in each of the three (3) action research cycles at various 
stages: 
" Developing a plan of critically informed action to address a desired change or 
improvement; 
" Acting to implement the plan; 
" Observing the effects of the action and conceptualising, theorising and 
generalising the action/experience; 
" Reflecting on the effects as a basis for further planning, and testing the 
concepts in new situations; and 
" Engaging in successive cycles of gaining knowledge through new concrete 
experience, reflection, conceptualisation and testing. 
2.5.1.1 Participatory action research (PAR) 
Participatory action research, as described by Whyte (1995: 289), is the 
dominant action research paradigm used in the study. Because the focus of the 
study is on organisational problem-solving rather than social transformation in 
the broader sense, the northern tradition rather than the southern tradition of 
participatory research, as described by Brown (1993: 252) was predominantly 
used and included both consultative and collaborative participation. 
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Babble and Mouton (2002: 66) describe consultative participation as when 
people are `... asked for their opinions and consulted by the researcher before 
interventions are made ... ': This was achieved through consultative forums that 
will be described in the various cycles of the study. 
Collaborative PAR is defined as researchers and local people working together 
on projects that are designed, implemented and managed by researchers 
(Cornwall & Jewkes, 1995: 1669). Collaborative participation was established 
through the various project teams. Because the size of most companies poses a 
problem in carrying out PAR, in most projects dealing with large organisations 
the actual reflection work is done by a small work group (Grundy, 1986: 29). A 
core project team was in place for the duration of the study and was added to or 
adapted in each cycle. The details and rationale of how the collaborative project 
team changed and the use of consultative forums was described in each cycle. 
As in action research, PAR uses four (4) primary steps, namely reflection, 
planning, action and observation (Zuber-Skerritt, 1995: 13). These research 
steps exist interdependently and follow each other in a spiral or cycle. Figure 2.1 
illustrates the spiral action of action research used in this project as described by 
Zuber-Skerritt and others (Zuber-Skerritt, 1996: 95 and O'Brien, 1998: 6). 
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Figure 2.1: The spiral action of action research (Zuber-Skerritt, 1996: 95 
and O'Brien, 1998: 6) 
Reflection in PAR is the step where the research participants examine and 
construct, then evaluate and reconstruct their concerns (Grundy, 1986: 28). 
Formal reflection was undertaken at regular intervals by myself, as well as 
through steering committee meetings, project team meetings and consultative 
forums. 
Planning in PAR is constructive and arises during discussions among the 
participants. After each process of reflection, the project team, through a 
participative process with key representatives of stakeholders, developed action 
plans to address the next steps (Eldin & Levin, 1991: 131). The integration of the 
ODR MOC® methodology provided the change evaluation component as 
suggested by Whyte (1995: 289). 
Action in the cycle occurs when the plan is put into place. The action is 
deliberate and strategic. It differs from other research methods in that the action 
or change happens in reality and not just as an experiment or "... just to see if it 
works ... " (Grundy, 1986: 28). In this study "action" was implemented and 
measured across all hospitals in the group. This was a deliberate and strategic 
choice rather than doing a pilot, since the aim of the research was to develop a 
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system for the management of pharmaceutical and surgical consumable 
products for the group as opposed to one (1) hospital. 
Observation in PAR is the "research" portion of PAR where challenges outlined 
in the plan are observed for their effects and the context of the situation 
(Kemmis & McTaggart, 1992). As with the action phase, observation ranged 
over the total group of hospitals. 
2.5.2 Adapted research paradigm 
Because change management was an important component in the 
implementation of the system across all hospitals, I combined the ODR MOC® 
methods as described in section 2.4. with the model of emancipatory action 
research and organisational change presented by Zuber-Skerrit (1996: 99). The 
adapted model is illustrated in Figure 2.2. The specifics of the steps used and 
how these methods were used interchangeably, were discussed in the relevant 
cycles. 
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2.5.3 Karlsen's action research model (1991) 
Karlsen's (1991: 148) action research model, as portrayed in Figure 2.3, 
provided an important link to differentiate between the objectives of the business 
project and the action process linked to the research objectives. Whilst the 
business project focused on meeting financial targets and maximising leverage 
without compromising therapeutic outcome, the research project aimed to 
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develop an integrated system for the management of pharmaceutical and 
surgical consumable products. 
Research Action 
ALIF 
1. Formulating the approach to the problem 
New New 
Knowledge 2. Design / planning Solutions 
3. Acquiring data 
4 . Analysis of data 
5. Reflection / interpretation of the results 
Figure 2.3: Karlsen's action process and action research model (Karisen, 
1991: 148) 
As stated by Karlsen (1991: 149), in contrast to the practitioner, the researcher in 
this model is responsible for both sides of the process. This was also the case in 
this study where I was both project leader of the business project and the 
researcher. The business solutions were carried out together with the project 
team, whilst the research aspect, the development of the integrated system, 
including the identification and compilation of its processes and tools, was my 
work. 
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2.6 RESEARCH DESIGN AND RESEARCH METHODS 
The research design is described as the type of research, the research strategy 
applied and the context of the study (Burns & Grove, 2001: 27). A summary of 
the methods and design in each cycle is indicated in Table 2.1. 
Table 2.1: Summary of the research methods and design 
CYCLE RESEARCH 
DESIGN 
UNIT OF 
ANALYSIS 
DATA GATHERING DATA 
ANALYSIS 
RESULT 
1 " Descriptive; " Processes and " Project team " Content " Process for 
" Exploratory; procedures for meetings and analysis. product 
and the management minutes; selection; 
" Qualitative. of pharmaceutical " Compliance " Product data 
and surgical reports; base; and 
consumables " Observation of " Draft integrated 
across twenty- pharmaceutical and system for the 
four (24) AHL surgical product management of 
acute-care purchasing data; pharmaceutical 
hospitals. and and surgical 
" ODR tools. consumables. 
2 " Descriptive; " System for the " Reflections of the " Inductive " Expanded 
" Exploratory; management of project team and from integrated 
and pharmaceutical researcher on results of system and 
" Qualitative. and surgical shortcomings of cycle 1; Improved 
consumables; cycle 1; and implementation 
and " Observation of " Content process. 
" Implementation pharmaceutical and analysis. 
process across surgical product 
24 AHL acute- purchasing data; 
care hospitals. " Compliance 
reports; 
" Consultative 
forums; and 
" Literature 
examination. 
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CYCLE RESEARCH UNIT OF DATA GATHERING DATA RESULT 
DESIGN ANALYSIS ANALYSIS 
3 " Qualitative; " Processes and " New acquisitions " Content " Verified, 
" Descriptive; procedures for merger project analysis. expanded 
and the management team meetings and integrated 
" Exploratory. of pharmaceutical minutes; system for the 
and surgical " Compliance management of 
consumables in reports; and pharmaceutical 
19 newly acquired " Observation of and surgical 
acute-care pharmaceutical and consumables 
hospitals. surgical product 
purchasing data. 
CO NCLUSION 
" Descriptive; " Processes and " Literature " Content " Integrated 
and procedures for examination. analysis. system for the 
" Exploratory. the management management of 
of pharma- pharmaceutical 
ceuticals and and surgical 
surgical consumables 
consumables as across a group 
developed in the of private 
three (3) action hospitals; and 
research cycles; " Recommenda- 
and tions 
" International and 
national literature. 
2.6.1 Type of research design 
A qualitative design was applied in this study. Qualitative research is used to 
generate knowledge, and uses structured and unstructured observation and 
communication as a means of gathering data (Burns & Grove, 2001: 27). 
Qualitative data gathering in this study was done through a number of different 
processes, namely steering committee reviews; project team minutes of 
meetings, reports, consultative forums and workshop notes and observations. 
The qualitative numerical data followed a longitudinal descriptive research 
design with measurable variables identified in the cycles then tracked over an 
extended period of time. 
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2.6.2 Research strategy 
The research strategy was exploratory and descriptive. Exploratory studies are 
undertaken when a new area or topic is being investigated (Polft & Hungler, 
1999: 18). In this study, an exploratory approach was followed in order to: 
" Address thematic concerns relating to the management of pharmaceuticals 
and surgical consumables in AHL; 
" Identify and develop the elements of the integrated system; 
" Identify practices that had become obsolete and had to be changed; 
" Formulate concepts and tools to support the implementation; and 
" Identify opportunities and practice improvements. 
Description is integral to the process of exploration adopted for this study and 
was done through the systematic approach of action research in three (3) 
cycles. The descriptive researcher is concerned with observing, describing and 
documenting aspects of events or situations as they occur naturally, and uses 
the information obtained to form the foundation for the development of theory (in 
this case, the development of the system) (Cormack, 2000: 214 and Babbie & 
Mouton, 2002: 80). 
2.6.3 Independent contribution by the researcher 
Although action research must be collaborative and conducted within a group, 
research at doctoral level has to be an independent piece of work of the 
researcher and an original contribution to knowledge in the field under study 
(Perry & Zuber-Skerritt, 1992: 205). It is therefore important to describe the 
relationship between the research study and core action research in which I 
show the independency of my work. 
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Participatory action research was achieved in this study by applying strategic 
and change management actions through the three (3) cycle spirals of planning, 
acting, observing and reflecting. 
The research study involved: 
" Collaboration - the researcher (myself) and local people working together on 
the project that was designed, initiated and managed by myself; 
" Consultation - where I asked people for their opinions and consulted with 
them before interventions were made; and 
9 Independent work of the researcher (myself). 
The relationship model (Zuber-Skerritt, 2000: 92-93) between thesis research, 
core action research and thesis writing was adapted for this study to describe 
the independent work of the researcher (myself) and is reflected in Figure 2.4. 
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INDEPENDENT CONTRIBUTION B Y THE RESEARCHER 
Planning the thesis Observations in the thesis 
" Develop the research problem from general " Describe the research process and 
thematic concerns (Submission 1) procedures followed for data 
" Complete and describe the literature survey gathering and data analysis 
regarding the management of pharmaceutical and throughout the study (Submissions 
surgical consumables nationally and internationally 1,2 and 3) 
(Submission 1) Evaluate the reflection results of 
" Compare literature within the value and operational each cycle for application in light of 
requirements of the business within the contextual the literature and contextual 
framework of the study (Submissions 1,3, and 4) framework of the study 
" Describe the design and rationale (Submissions 1, (Submissions 2,3 and 4) 
2 and 3) 
" Justification of the methodology (Submissions 1,3 NOTE: Submission 4= Innovation Report 
and 4) 
Core action research: Collaboration with 
project team within contextual 
' framework of the study: Researcher s 
Role: 
" Directing, coaching and leading the 
project teams 
" Providing strategic direction, 
methodology and allocating tasks to °t"'" A` 
project teams 
" Identifying, gathering, storing, analysing 
data and formulating actions "V'-'PL- Z 
" Building and presenting feedback on 
I 
progress and next steps to business «A 
" Planning and running project team 
ý-ý 
workshops, training sessions and 
meetings 
" Writing and/or reviewing, editing 
Wed Pbn C 
policies and procedure ` 
(Submissions 2a, b and c) At 
Cbý 
"ýý 
Independent contribution by the researcher: Reflection thesis 
" Reflection by the researcher (Submissions 1,2,3 and Innovation Report) 
Analyse and describe the reflection by the researcher and participants (Submission 2) 
" Analysis and evaluation of results of action (content and process) in light of the literature 
(Submissions 3 and 4) 
" Describe the propositional conclusions from the research with knowledge claims (Submissions 
3 and 4) 
" Summarise the research strategy and the various qualitative techniques used in the study 
(Innovation Report) 
Describe recommendations for further research (Submissions 3 and 4 
Figure 2.4: Relationship between core research and the researcher's 
independent contribution: Adapted from Perry & Zuber-Skerritt (1992) 
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2.6.4 Context of the study 
Unlike the quantitative researcher, who, in order to increase generalisability, 
usually aims at analysing variables in isolation from the context or the setting, 
the qualitative researcher's aim is to describe and understand events within the 
context in which they occur (Babble & Mouton, 2002: 272). 
This study was undertaken within the contextual framework of a healthcare 
company in the private sector in South Africa, namely Afrox Healthcare (AHL). 
The background of this context was described in Chapter 2 of Submission 1 and 
summarised in Section 1.3 of this submission. 
2.6.5 Ethical considerations 
Ethical considerations taken into account in this study were based on the 
principles for action research fieldwork as described by Winter (1996: 16) and 
Morton-Cooper (2000: 41). These included: 
" Informed consent for this study was obtained from the General Manager 
HealthCare Services at the time when the project was initiated and later from 
the newly appointed managing director of AHL in 2002; 
" The right to privacy, as described by Burns and Grove (2001: 200), was 
ensured by not linking the participants of the project team to the results of the 
discussions. No participant is referred to by name and no individual hospital 
names were used in this study; 
" Adequate feedback and reporting of the study's progress (Morton-Cooper 
2000: 42) was provided through ongoing feedback to the MD, who had 
agreed to be the mentor for the research study as well as through a steering 
committee of senior managers in AHL that was formed in Cycle 2; and 
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"I also used the company code of ethics and the five (5) principles of the code 
of ethics for pharmacy to guide me as researcher (ASHP, 1996: 1805). No 
known or expected harmful effects to participants or patients were expected 
or have resulted from this study. 
2.7 TRUSTWORTHINESS OF THE STUDY 
The key criterion or principle of good qualitative research is found in the notion 
of trustworthiness, and a qualitative study cannot be called transferable unless it 
is credible, and it cannot be deemed credible unless it is dependable (Babbie & 
Mouton 2002: 276) 
The criteria for credibility as described by Babbie and Mouton (2002: 277) and 
their application in the study are summarised in Table 2.2. 
Table 2.2: Application of criteria for credibility (Babbie & Mouton, 2002: 
277) 
CRITERIA FOR CREDIBILITY 
OF QUALITATIVE STUDIES 
APPLICATION IN THE STUDY 
Prolonged engagement The study was conducted over three (3) action research cycles 
which spanned over three (3) years corresponding to the 
financial year cycles of AHL. 
Further monitoring and application of the system continued 
subsequently and outcomes are presented up to the end of the 
2003 financial year. 
Persistent observation Outcomes of the implementation of the integrated system were 
measured monthly. Monthly progress was reviewed with 
Consistently pursue collaborative team members, with myself as leader. 
interpretations in different ways, 
in conjunction with a process of 
Further independent observations were conducted by the 
constant and tentative analysis. 
researcher (myself) throughout the study as described in each 
submission. 
A further literature examination by myself as researcher to 
compare the integrated system to other systems of management 
resulted in additional recommendations for improvements and a 
further conceptualisation of the integrated system. 
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CRITERIA FOR CREDIBILITY APPLICATION IN THE STUDY 
OF QUALITATIVE STUDIES 
Triangulation The outcomes of the integrated system were measured across 
the group and in each individual hospital. 
The best way to elicit the various 
and divergent constructions of 
Evaluation was conducted with different collaborative team 
reality that exist within the 
members and by myself (the researcher) as well as with steering 
context of a study is to collect 
committees within the business. 
information about different An independent test of the integrated system in 19 newly 
events and relationships from acquired hospitals was conducted in Cycle 3. 
different points of view. 
Referential adequacy Outcomes of the integrated system were available in monthly 
reports, minutes of meetings, notes from workshop and from the 
What materials are available to management and measurement tools developed within the 
document your findings. integrated system. 
Examples of tools and materials were provided as appendices in 
the relevant submissions 
Peer debriefing The steering committees established in the implementation of 
the integrated system as described in Submissions 2b and 2c, 
This is done with a similar status included three (3) fellow members of the AHL executive team. 
colleague (not with a junior or 
senior peer) who is outside the 
These committees/peers provided input into the study, and 
context of the study who has a 
provided input into next steps. I also examined the literature 
extensively and repeatedly in order to refine the conceptual 
general understanding of the framework and to compare the integrated system to other 
nature of the study, and with systems of management internationally. 
whom you can review 
perceptions, insights, and 
analyses. 
Member checks The validity of individual hospital data was checked monthly. 
Extensive discussions were held with collaborative team 
Go to the source of the members to test interpretation. 
information and check both the 
data and the interpretation. 
The independent test of the system further validated the 
findings. 
A paper trail of reports, minutes of meetings, workshop notes, 
measurement and management data was established. 
Transferability was a further element of trustworthiness applied in the study. 
According to Lincoln and Guba (1985: 290) transferability is achieved through 
thick description and transferability to similar context. Thick description was 
achieved through a comprehensive description of all of the research procedures 
followed. Transferability to a similar context was achieved through the 
independent test of the integrated system in 19 newly acquired hospitals in 
Cycle 3, and again in the implementation in four (4) further hospitals as will be 
described in section 6.3 of Chapter 6. 
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2.8 SUMMARY 
The research design and research methods of the study were summarised in 
this chapter, including the change management methods used and the action 
research methodology. Trustworthiness was discussed based on the criteria for 
credibility and transferability. I will now provide an overview of the three (3) 
action research cycles of the study. 
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CHAPTER 3 
DETERMINING WHAT IS NEEDED TO DEVELOP AND MAINTAIN AN 
INTEGRATED SYSTEM FOR THE MANAGEMENT OF PHARMACEUTICAL 
AND SURGICAL CONSUMABLE PRODUCTS 
3.1 An overview of the three (3) 
action research cycles 
3.2 Research paradigm 
3.3 Cycle 1: Identification, 
development and 
implementation of the first 
four (4) processes 
3.4 Cycle 2: Identifying and 
addressing the gaps in the 
draft integrated system 
3.5 Cycle 3: Independent test 
of the adapted integrated 
system 
3.6 Progressive outcomes and 
overall impact of the 
integrated system 
3.7 Summary 
3.1 AN OVERVIEW OF THE THREE 
(3) ACTION RESEARCH CYCLES 
The core of the study consisted of three 
(3) action research cycles, during which I 
set out to determine what was needed to 
develop, implement and evaluate an 
integrated system for the management of 
pharmaceutical and surgical consumable 
products across the hospitals in AHL. 
Figure 3.1 provides a diagrammatic overview 
of the three (3) cycles, showing the research questions, thematic concerns and 
results of each cycle. The results shown in the figure include the outcomes of 
implementation, which is covered in this chapter, as well as the results relating to 
the research objective, which will be described in the next chapter. 
As stated in Chapter 2, I used Karlsen's action research model (Figure 2.3: 26) as 
a link to differentiate between the objectives of the business project and the 
research objectives. This chapter will conclude with an overview of the progressive 
outcomes, and the overall impact of the integrated system on achieving the 
business objectives. I will also provide a diagrammatic overview of the integrated 
system as it progressed over the three (3) action research cycles, and summarise 
the features and key unique features of each of the processes of the system in this 
chapter. 
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As shown in Figure 3.1, reflection involved a review of thematic concerns and the 
development of reflective questions in each of the three (3) cycles. These then 
formed the basis of the planning steps. The development and/or implementation of 
the plan resulted in the action steps. To evaluate the developed system in each 
cycle, outcomes of implementation were measured and discussed in the observe 
steps. This led to further reflections and thematic concerns and from that further 
questions were formed and so forth. 
Each of the cycles also followed a systems approach of input-process-output with 
feedback loops as shown in Figure 3.2. Since feedback from each process and 
step was used as input for further development of the integrated system, 
conclusions (outcomes) related to each step were included in the descriptions 
where appropriate. 
Figure 3.2: The systems approach (Roos, 1996: 137) 
3.2 RESEARCH PARADIGM 
As stated in chapter 2, the dominant action research paradigm used in the study 
was based on the northern tradition of participatory action research (PAR) using 
both collaborative and consultative participation. 
A summary of the collaborative project teams and consultative participants for 
each of the action research cycles is shown in Table 3.1. The members of the 
various collaborative teams were chosen on the basis of their experience and 
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knowledge within their specific fields of expertise. The consultative participants 
were selected to represent key stakeholders in the organisation who would be 
affected by the proposed changes or who were specialists in a particular category 
of pharmaceutical or surgical consumable products. 
Table 3.1: Summary of collaborative and consultative teams used in the 
three action research cycles 
Researcher (myself) and local people work 
together on project designed, initiated and 
managed by the researcher 
1 
2 
" Core Formulary Project Team from Afrox 
Pharmacy Management Services (APMS) 
staff; and 
" Product Selection/Formulary Design 
Project Team from APMS staff consisting 
of: 
o Pharmaceutical product specialist; 
o Surgical consumable product specialist; 
and 
o Procurement and information specialist. 
" Formulary IT Project Team consisting of: 
o Core Formulary Project Team; 
o APMS price file manager; and 
o The AHL manager responsible for IT in 
APMS. 
" Project leader (myself). 
As for Cycle 1, with the addition of: 
A human resources professional; and 
"A communications professional. 
As for Cycle 1 with the exception of: 
" Core Formulary Project Team with one (1) 
additional pharmacist from the PresMed 
group; and 
" Formulary IT Project Team, including a 
PresMed IT specialist. 
People asked for opinions and consulted 
by the researcher (myself) before 
interventions are made 
" Operations managers from APMS staff 
responsible for processes, procedures 
and performance of pharmacy in the 
hospitals; 
" Pharmacy managers in Afrox 
Healthcare Limited (AHL); 
" Nursing managers in AHL; 
" Information technology (IT) manager 
responsible for IT systems in APMS; 
" AHL senior management and hospital 
managers; 
" Specialist doctors and nurses; 
" Pharmacology specialists; 
" Suppliers; and 
" Relevant IT professionals from the IT 
department in AHL. 
As for Cycle 1, with the addition of: 
Formalised Formulary Project 
Steering Committee consisting of: 
o General manager (GM) 
responsible for APMS; 
oA GM from the acute-care hospital 
division; 
o The IT manager; and 
o Myself as project leader. 
" As for Cycle 1 with the exception of: 
" Presmed Integration Executive 
Steering Committee; 
" Operations managers from APMS staff 
responsible for processes, procedures 
and performance of pharmacy in the 
hospitals with one (1) additional 
pharmacy operations manager; 
" Pharmacy managers in PresMed 
hospitals; 
" Nursing managers in PresMed 
hospitals: and 
" Information technology (IT) 
manager with knowledge of 
PresMed IT systems. 
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Collaborative team members worked with the project team leader (myself) to 
deliver different components of the project. Each had a direct reporting relationship 
to me, except for the HR and communications professionals who were co-opted in 
Cycle 2 for a specific time period. My role, as project leader and researcher, was 
to: 
" Provide strategic direction, as well as the research and project methodology; 
" Allocate tasks to the team members; 
" Direct, coach and lead the project teams; 
" Identify, gather, store and analyse data and formulate actions; 
" Build and present feedback on progress and ensuing steps to the business; 
" Plan and run project team workshops, meetings and training sessions; and 
" Compile and/or review and edit policies and procedures. 
3.2.1 Research methods 
The unit of analysis and different methods of data gathering for each cycle was 
described in Table 2.1: 27. In addition, tools from the ODR MOC® methodology, 
such as the MOC® Change Project Description Form, were used to gather data 
during group work sessions of both the collaborative and consultative participants. 
All data gathered was documented in minutes of meetings, formal reports, 
presentations to the executive management steering committee of AHL and new 
processes and protocols for the management of pharmaceutical and surgical 
consumable products. 
A step-by-step data analysis approach was followed by applying a gap analysis 
strategy between the existing situation and the desired outcome of the cycle. Due 
to the exploratory nature of the research, it was not always possible to separate 
data gathering and data analysis in each step. These were therefore presented 
simultaneously using a descriptive approach. 
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At the end of each cycle, an inductive approach was followed in line with Karlsen's 
action research model as described in Chapter 2, in order to develop the 
integrated system further. In each cycle whilst, the project team focused on 
activities relating to achieving the goals of the business project, I was responsible 
both for leading the business project as well as developing and revising the 
integrated system as the aim of the study. 
The progression of the integrated system over the three (3) cycles arising from the 
inductive approach (as shown on the right-hand side of Figure 2.4: 31 in this 
submission) will be discussed in Chapter 4. 
In this chapter I will provide an overview of each of the three (3) action research 
cycles which progressed as follows: 
" In Cycle 1, the first four (4) processes of the integrated system were identified, 
developed and implemented across all hospitals in AHL (Section 3.2); 
" In Cycle 2, gaps in the draft integrated system were identified and addressed 
(Section 3.3); and 
" In the third cycle of action research the adapted and enhanced integrated 
system was independently tested in 19 newly acquired hospitals whilst 
continuing in existing hospitals (Section 3.4). 
I will provide an overview of the steps followed, highlight the thematic concerns 
and briefly describe the key implementation components and present a summary 
of the outcomes with regard to each cycle. 
To conclude this chapter, the outcomes of all three (3) cycles will be compared 
and discussed (Section 3.5). By the end of the action research cycles the 
integrated system had been implemented across all 43 acute-care hospitals in 
AH L. 
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3.3 CYCLE 1: IDENTIFICATION, DEVELOPMENT AND IMPLEMENTATION 
OF THE FIRST FOUR (4) PROCESSES 
Figure 3.3 shows a graphic representation of the progress of Cycle 1, which began 
with a review of the thematic concerns and reflective questions. 
ACTION 
RESEARCH 
STEPS 
Review of thematic concerns and reflective questions REFLECT N 
P 
U 
T Establishment of the project plan 2 PLAN 
FOCUS AREA 1 FOCUS AREA 2 FOCUS AREA 3 
Development of a Development of Development of 
process for the information the hospital 
product selection technology implementation 
for support systems process P pharmaceutical for the 
R and surgical management of ACTION 
p consumable pharmaceutical 
C products and surgical 
E consumable 
S products 
S 345 
111 
FOCUS AREA 4 
Measurement and management tools 6 
Implementation 7 
Outcomes of implementation 6 
OBSERVE 
T 
C 
O Draft integrated system for the management of 
M pharmaceutical and surgical consumable products 
E 9 
S 
CYCLE 2 J 
REFLECT 
Figure 3.3: Graphic representation of the progression of Cycle 1 
A project plan was established in which four (4) key focus areas were identified 
(step 2). The processes developed as part of the exploratory work in the four (4) 
focus areas (steps 3-6) were implemented as a draft system across all hospitals 
(step 7), and outcomes were measured over a 3-month period (step 8). 
The result of the cycle was a draft integrated system for the management of 
pharmaceuticals and surgical consumables (step 9). Each of the steps illustrated 
in Figure 3.3 was described in detail in the study and can only be summarised at 
high level in this overview. 
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3.3.1 Thematic concerns and identifying the processes of the integrated 
system 
The input phase of Cycle 1 included the review of thematic concerns and reflective 
questions, the identification of the processes and the establishment of the project 
plan. Thematic concerns define the substantive areas in which a group decides to 
focus its improvement strategies (Kemmis & McTaggart, 1992: 11). 
In Cycle 1 these were derived from the background summarised in Chapter 1, 
together with the answers to the questions on the MOC® Change Project 
Description Form, which was completed in a workshop with the Core Formulary 
Project Team and representatives of the collaborative participants as shown in 
Table 3.1. 
Four (4) focus areas were identified, namely: 
" The development of a process for product selection for pharmaceutical and 
surgical consumable products (section 3.3.2.1); 
" The development of the information technology (IT) support systems (section 
3.3.2.2); 
" The development of the hospital implementation process (section 3.3.2.3); and 
" Measurement and management tools (section 3.3.2.4). 
Together with "implementation" the progression of these four (4) focus areas 
formed the process component of Cycle 1. A summary of the thematic concerns 
and group reflective questions, mapped against the focus areas is presented in 
Table 3.2. 
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Table 3.2: Thematic concerns and group reflective questions mapped 
against the project focus areas 
THEMATIC CONCERNS GROUP REFLECTIVE QUESTIONS COMPONENT/FOCUS 
AREA 
Escalating cost of How can the escalating costs of Product selection 
pharmaceuticals and surgical pharmaceutical and surgical consumable Process (1). 
consumables. products be responsibly addressed? 
Growing number of different How can the number of product brands Product selection 
pharmaceutical and surgical kept across the group be managed? process (1); and 
brands. How can it be established which products " IT support for the 
are substitutable and which are not? formulary (2). 
Growing number of How can the lowest cost on Product selection 
reimbursement systems where pharmaceuticals and surgical process (1). 
the provider (hospital) is consumable products used in different 
expected to take risk, e. g. per risk models be ensured? 
diems and fixed fees. 
Loss of mark-up on How can margins on pharmaceuticals Product selection 
pharmaceutical and surgical and surgical consumables without process (1). 
consumable products in the compromising cost to patients and 
fee-for-service reimbursement funders be retained and improved? 
model will impact on margins 
and profitability. 
Doctor resistance to How can doctor support for product " Hospital 
challenging their choice of choices and correct usage of such be implementation 
products. ensured? (3); and 
" Product selection 
process (1). 
Maintain optimal therapeutic How can it be ensured that product Product selection 
outcomes. Credibility of choices have credibility with stakeholders process (1). 
product choices and process. and do not compromise quality care or 
quality service delivery? 
Leverage group synergy so How can it be ensured that the group Hospital 
that the total is greater than (AHL) indeed influence product choice implementation 
the sum of parts. and utilisation across all hospitals in (3). 
order to leverage that power with 
suppliers? 
Implement solutions across all How can the full implementation of the " Hospital 
hospitals. system for the management of implementation 
pharmaceutical and surgical (3). 
consumables across all AHL hospitals be 
ensured? 
Information database and " What information is needed to determine Information 
systems capability are critical strategy and to drive the project? technology (IT) 
to support future management How can the use of the electronic support (2). 
systems. environment to achieve set objectives be 
maximised? 
Ongoing management and How will the effective ongoing " Measurement and 
maintenance. management of pharmaceutical and management tools 
surgical consumable products be (4). 
ensured and not end up as just a `once 
off" ro'ect? 
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3.3.2 Development and implementation of the four (4) processes 
Although the development of the four (4) processes was described separately, the 
actions progressed simultaneously and overlapped each other. 
3.3.2.1 Product selection process 
Figure 3.4 provides an overview of the rationale for the steps in the product 
selection process for pharmaceutical and surgical consumable products. The 
sequential steps are indicated with an arrow, and those bracketed occurred 
simultaneously. 
CLASSIFICATION SYSTEM The classification system for 
FOR PHARMACEUTICAL pharmaceutical and surgical 
AND SURGICAL consumable products was required to 
provide a system to categorise and CONSUMABLE 
compare like products for PRODUCTS rationalisation. 
1- 
PROCESS FOR Since there were over 28,000 products 
PRIORITISATION OF in use across the organisation, a 
CATEGORIES method to prioritise the product 
categories that would be considered for 
rationalisation, had to be established. 
1. 
CLINICAL ANALYSIS 
Clinical analysis was required to 
establish the clinical efficacy, safety 
and effectiveness of pharmaceutical 
and surgical consumable products, in 
order not to compromise quality care. 
SUPPLIER EVALUATION 
FINANCIAL ANALYSIS 
The different suppliers of 
pharmaceutical and surgical 
consumable products had to be 
evaluated according to an agreed set of 
criteria, to ensure quality, reliability and 
consistency of supply. 
A financial evaluation of products in the 
same category was needed to establish 
whether the product met the financial 
goals of the project. This step followed 
after initial supplier negotiations. 
1 
For the final selection the information 
from all the previous steps in the 
FINAL SELECTION process together with input from 
Product and Supplier selected 
key stakeholders were 
combined. This resulted in 
rationalisation of products and 
Figure 3.4: An overview of the product selection process for 
pharmaceutical and surgical consumable products 
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The product selection process for pharmaceutical and surgical consumables was 
derived from: 
" The examination of processes used internationally and nationally; 
" Consideration of existing processes in the management of pharmaceutical and 
surgical consumable products; and 
" Consideration of the goals of the project. 
The key differences from international trends were in the integration of 
pharmaceutical and surgical consumable products and in the approach adopted 
for the system development. Further discussion of these differences will be 
highlighted in the discussion of the review of the integrated system against the 
literature in Chapter 5. 
A detailed description of each of the six (6) steps was provided. As stated in 
section 4.2.1 of Submission 2A, no international system for classification for 
surgical consumable products was available for use. The development of a unique 
seven tier classification system for these products was therefore a critical step in 
enabling an integrated system. Further key unique features from the product 
selection steps and processes will be described in the presentation of the draft 
integrated system in Chapter 4 of this submission. 
3.3.2.2 Information technology (IT) support systems 
In Chapter 5 of submission 2A, I described the methods and processes followed to 
identify and develop the IT support systems for the management of 
pharmaceutical and surgical consumable products, namely: 
" Group procurement information (GPI) data warehouse; 
" The product database (PIPS) - the formulary IT carrier; and 
" Access to the formulary at hospital pharmacy level in the hospital billing IT 
system (MAC). 
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For each of these aspects the Formulary IT Project Team, with myself as team 
leader, had to: 
" Examine existing IT systems within AHL that could support the requirements; 
" Convene consultative workshops with relevant consultative participants to 
obtain input on requirements and specifications; and 
" Consult and provide specifications to IT specialists that would provide the 
technology solutions for the requirements that were identified. 
Details of the development of the three (3) identified IT systems and their use in 
the integrated system were described in Chapter 5 of Submission 2A. The GPI 
data warehouse and the enhanced product database (PIPS) were both the first of 
these IT support systems in the private hospital industry in SA as was the ability to 
electronically link surgical consumable products to a classification system. Further 
key unique features and innovations of the information technology support 
systems will be described in the details of the draft integrated system in Chapter 4. 
3.3.2.3 Hospital implementation process 
The process for implementation across all hospitals was developed in focus area 3 
of Cycle 1. Targets for the change process were identified from the answers to the 
questions in the ODR MOC® Change Project Description Form. It was agreed that 
all pharmaceutical and surgical consumable products would be purchased and 
dispensed or distributed by the pharmacy department in each hospital. 
Changes to protocols and procedures were identified for implementation during 
Cycle 1, and a consultative process was followed with staff in AHL to agree on the 
process for implementation. Supportive processes put in place for hospital 
implementation included: 
" The establishment of a formulary "hot-line" for telephonic queries and 
assistance that was manned by the members of the Core Formulary Project 
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Team. Queries were monitored and also used as ongoing feedback for the 
process; 
" The development of a formulary newsletter with relevant information, which 
was distributed to all pharmacy managers and hospital managers; and 
"A formulary slide presentation, which included all the key concepts of the 
procedures and product selection process. 
Doctor implementation in individual hospitals was the responsibility of pharmacy 
managers with support from nursing staff and hospital managers. Pharmacy 
managers were inducted on the formulary implementation requirements in a group 
workshop. 
3.3.2.4 Measurement and management tools 
The overall success of the project depended on the ability to achieve the changes 
in product usage in order to realise the leveraged benefits and meet financial 
targets. Without successful implementation across all hospitals: 
" The goals of the project and financial improvements would not be realised; 
" The risks in per diem and fixed fee tariffs for the hospitals and AHL as a whole 
would increase and affect performance; and 
" The integrated system for the management of pharmaceutical and surgical 
consumable products would break down. 
Measurement and management tools were identified and developed for each of 
the processes as summarised in Table 3.3. 
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Table 3.3 Summary of measurement and management tools: Draft 
integrated system for the management of pharmaceutical and 
surgical consumable products 
FOCUS AREA MEASUREMENTS MANAGEMENT TOOLS 
Focus area 1 Value of pharmaceutical Core Formulary Project Team trained 
and surgical to use the Cognos Impromtu0 and 
Process for product consumable products Cognos Powerplay® tools to enable 
selection for analysed; and them to extract and analyse further 
pharmaceutical and Percentage reduction in detailed information from the PIPS 
surgical consumable number of products. database and GPI data warehouse. 
products. 
Focus area 2 GPI data warehouse: List of products in the suspense file 
percentage of total per hospital and for the entire group; 
Information technology value of products in the and 
support systems for the suspense file; and Core Formulary Project team trained to 
management of PIPS database: use the Cognos Impromtu® and 
pharmaceutical and Percentage of total Cognos Powerplay® tools to enable 
surgical consumable products classified. them to extract and analyse further 
products. details on classification from the PIPS 
database. 
Focus area 3 " Compliance to product " Compliance report with list of non- 
selection. Line formulary products ranked by total 
Hospital formulary compliance. value purchased. 
implementation. 
The measures of progress for the product selection process were based on 
value of spend covered and the percentage reduction in the number of products. 
For the IT support systems the value of reliable and accurate information was 
recognised as an important competitive advantage for AHL. In the GPI data 
warehouse, inaccurate and poor quality data, e. g. wrong product codes, pack 
sizes or suppliers, were discarded into a "suspense" file and excluded from the 
data warehouse. Thus data on usage and value would be incomplete. 
The degree to which classification had been completed was also included as a 
measure in the IT system process, as without the classification being completed it 
was not possible to proceed with product selection. 
Compliance to the formulary, as measured by the extent to which the actual 
chosen product was used, was a key measure of the result of hospital 
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implementation. Each time a non-formulary product was used it would decrease 
the percentage compliance. This measure was called product line compliance. 
A target of 70% compliance was set for pharmacy managers. To enable them to 
improve the compliance percentage, a formulary compliance report for 
pharmaceutical and surgical consumable products was developed for each 
hospital. 
3.3.3 Outcomes of Cycle I 
The outcomes of the measures for Cycle 1, monitored over a three-month period, 
were as follows: 
" The product selection process had been completed for 24% of total products 
purchased (37% of pharmaceutical products and 8% of surgical consumable 
products); 
" The percentage reduction in the number of products was 74% (from 2058 to 
528 products); 
" 31 % of products were classified in the product database (51 % pharmaceuticals 
and 15% of surgical consumable products); and 
" Compliance in terms of all 19 hospitals was 44,3% for pharmaceutical products 
and 52% for surgical consumable products. Individual hospital compliance 
showed that the variance in product usage was not from hospital to hospital but 
within each hospital. 
To conclude Cycle 1, a diagrammatic overview of the integrated system was 
developed by myself (the researcher) as a draft integrated system and the 
processes and sub-processes described. This will be covered in Chapter 4. 
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3.4 CYCLE 2: IDENTIFYING AND ADDRESSING THE GAPS IN THE DRAFT 
INTEGRATED SYSTEM 
The objectives of Cycle 2 were: 
" To identify the gaps resulting from the implementation of the system in Cycle 1; 
" To develop support elements for the identified gaps; and 
" To verify the adjustments by retesting the system in AHL hospitals. 
The progression of Cycle 2 is shown in Figure 3.5. As with Cycle 1, a systems 
approach of input, process and outcomes as well as the action research steps of 
review, plan, action and observe were followed. 
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Figure 3.5: Graphic representation of the progression of Cycle 2 
The input phase of Cycle 2 (step 1) involved the review of the draft integrated 
system and the outcomes of Cycle 1, the identification of gaps in the draft 
integrated system and the establishment of a plan to address the gaps. This 
included a review of the change management methods. The process phase (step 
2) included enhancing existing processes, the development of new processes and 
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the implementation of these in all hospitals. Finally, in step 3, the outcomes of the 
implementation of the adapted integrated system were measured. 
3.4.1 Review of the draft integrated system 
The outcomes of Cycle 1 were lower than expected, with specific reference to: 
The target of 70% compliance set for pharmacy managers was not achieved; 
" The process for product selection took longer than expected and as a result 
only 24% of products used were covered by the formulary; and 
While the potential for the reduction in the number of products was considered 
good, buy-in was not as effective and the same level of product reduction was 
not achieved at hospital level. 
Thematic concerns and group reflective questions were examined and actions for 
improving the existing processes were identified. Two (2) further processes were 
added to address some of the gaps identified, namely pharmacy capability 
development and supplier strategy and interface processes. Table 3.4 summarises 
the thematic concerns, group reflective questions and identified actions for Cycle 
2. 
Table 3.4: Thematic concerns, group reflective questions and actions 
identified in Cycle 2 
FOCUS AREA THEMATIC 
CONCERNS 
GROUP REFLECTIVE 
QUESTIONS 
ACTIONS 
1. PRODUCT Cost of How can it be ensured that " Extend the scope of 
SELECTION pharmaceuticals and the products chosen have the product 
PROCESS surgical consumables both the impact on costs and selection process 
in per diem and fixed the margin improvement that for pharmaceuticals 
fee reimbursement the formulary is design to and surgical 
system. deliver? consumable 
" What gaps are there in products; 
Impact on margins and ensuring the correct quality " Identify and address 
profitability of loss of of products are selected? the gaps in the 
mark up on fee-for- How can the feedback product selection 
service process on product quality be process; and 
reimbursement. enhanced? " Develop a formulary 
" What happens when new review/maintenance Credibility of the products are introduced? process. 
product selection When would it be appropriate 
process. to review the original product 
choices? 
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FOCUS AREA THEMATIC GROUP REFLECTIVE ACTIONS 
CONCERNS QUESTIONS 
2. IT SUPPORT The information " How can it be ensured that the " Establish a 
database and necessary resources are sustainable IT 
information technology available to address the gaps support system for 
systems capability are in information technology (IT) the integrated 
critical components of support? system; 
the integrated system " How can it be ensured that the " Provide the IT 
for the management of information technology (IT) functionality for the 
pharmaceutical and systems continue to support enhanced integrated 
surgical consumable the integrated system on an system; and 
products. ongoing basis? " Complete the pre- 
event formulary 
application to 
provide electronic 
access to the 
formulary at hospital 
level. 
3. HOSPITAL " Compliance is less How can it be prevented that " Develop a 
IMPLEMEN- than what was the pharmaceutical and sustained 
TATION expected and surgical consumable communication 
PROCESS required. products formulary becomes strategy to all 
" Doctor and staff just a theoretical list of stakeholders; 
resistance is approved products? " Agree and align 
impacting on the How can the support and performance 
effectiveness of commitment of staff and measures with 
implementation. doctors working in the project objectives 
" The initial hospitals be gained? for all relevant staff; 
enthusiasm and How can it be ensured that " Establish and train 
commitment to the potential leveraging power formulary 
formulary process with suppliers is not implementation 
was wearing off. discredited? teams in each 
" There was a risk that " Do relevant staff have the hospital; 
commitments to skills to fully implement the " Improve the 
suppliers would integrated system? process for 
not be met. ensuring doctor 
buy-in: and 
" Provide appropriate 
information to 
pharmacy 
managers to defend 
formulary/product 
selection decisions. 
4. MEASURE- The ongoing Do the measurement and " Review 
MENT AND management and management tools meet the measurement and 
MANA- maintenance of the needs of the organisation and management tools 
GEMENT project could only be tell the full story? and ensure they are 
TOOLS sustained by relevant understood and 
measurements that effectively used at 
meet the needs of the all levels of 
organisation. management. 
NEW ACTIONS 
PROCESSES 
5. PHARMACY Develop and implement programs to ensure pharmacists have the clinical and 
CAPABILITY technical knowledge to support formulary implementation; 
DEVELOP- Develop and implement interpersonal skills training such as presenting, selling, 
MENT conflict handling and negotiation skills; and 
" Ensure ongoing pharmacy manager and pharmacist induction on the formulary 
system. 
6. SUPPLIER Develop a supplier strategy; 
STRATEGY Formalise the supplier interface process; and 
AND Develop and implement supplier representative policy. 
INTERFACE 
PROCES- L 
SES 
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3.4.2 Improvements and additions to the integrated system 
The improvements to the draft integrated system included enhancements of the 
existing four (4) processes as well as the addition of further processes. 
Enhancements to the development of a product selection process for 
pharmaceutical and surgical consumable products included the development of a 
product review process with a product trial process for surgical consumable 
products, as well as the addition of supplier-only standardisation, therapeutic 
substitution and formulary restrictions. The corresponding changes in information 
technology (IT) support systems were developed to meet the new product 
selection processes and the completion of electronic access to the formulary. To 
improve the process for implementation a role map and communication strategy 
were developed together with a method for doctor constituency analysis and the 
establishment and training of formulary implementation teams. In the 
measurement and management tools process, two (2) new measures were 
added in Cycle 2, namely compliance based on value spent and market share 
reports. 
One gap identified was the need to develop a process to ensure that pharmacists 
were fully skilled to drive and implement the formulary system in their respective 
hospitals. A second gap was a need to develop a supplier strategy and formalised 
interface with suppliers in order to maximise the potential to leverage purchasing 
power. I identified these processes as: 
" Pharmacy capability development; and 
" Supplier strategy and interface. 
To address the pharmacy capability development process, three (3) areas of 
development were identified, processes developed and implemented as described 
in the green shaded area of Table 3.4. 
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The need for a supplier strategy, which included formal interface processes, 
was highlighted by, amongst others, the fact that the lower than expected 
compliance level achieved in Cycle 1 created a risk that the leverage position 
achieved with formulary suppliers would be discredited. 
Figure 3.6 contains a graphic representation of the concepts of the supplier 
strategy. 
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Figure 3.6: Graphic representation of the concepts of the supplier strategy 
The supplier strategy moved identified suppliers from 'approved suppliers' through 
to `formulary suppliers', 'strategic partners', and finally `strategic partners with risk 
sharing'. In addition to the supplier strategy, formal interface processes with 
suppliers, including requests for information (RFI), requests for quotations (RFQ) 
and a representative policy, were developed and implemented. 
3.4.3 Outcomes of implementation of the adapted and enhanced integrated 
system 
The outcomes of Cycle 2 were measured from April 1998 to September 1998, 
which coincided with the financial year-end of AHL. Outcomes were also 
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measured to September 1999, which was the start of Cycle 3. The outcomes 
encompassed the following: 
" The completion of the product selection process increased from 24% of total 
products purchased in Cycle I to 39% of products in Cycle 2 (49% of 
pharmaceutical products and 33% of surgical consumable products). This 
increased to 52% by September 1999; 
" The percentage reduction in the number of products decreased from 74% to 
68% and was sustained at that percentage by September 1999; 
" The total value of products classified in the product database increased from 
31% to 51% in September 1998 (57% pharmaceuticals and 46% of surgical 
consumable products). This increased to 67% by the following year. 
" Line compliance across all hospitals increased from 44% to 54% for both 
pharmaceutical and surgical consumable products; and 
" The new compliance measure, namely product value compliance, reached 
75% (77% for pharmaceutical products and 75% for surgical consumable 
products). 
Further discussion of the outcomes will be covered in the progressive outcomes 
and the overall impact of the integrated system in section 3.6 of this chapter. 
In Chapter 4,1 will show the progression of the graphic representation of the 
integrated system as the enhanced and adapted integrated system that was 
developed at the end of Cycle 2, as well as the improvements and additions to the 
processes and sub-processes that were described. 
In September 1999, AHL acquired a company known as PresMed, which included 
19 acute care hospitals, thereby enhancing its geographic spread across SA and 
providing the potential to achieve further economies of scale (Vice, 1999: 7). This 
led to the initiation of a third action research cycle which will now be discussed. 
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3.5 CYCLE 3: INDEPENDENT TEST OF THE ADAPTED INTEGRATED 
SYSTEM 
In September 1999, AHL expanded further through the acquisition of a 19 
hospitals, known as PresMed, making AHL the largest hospital group in the SA 
private healthcare sector at the time. According to the MD of AHL (Hogben, 
1999: 11) the focus of the newly merged organisation resulting from the acquisition 
of the PresMed group was to: 
" Optimise synergy across the group; 
" Transfer knowledge and experience across organisational boundaries; 
" Build an atmosphere of trust and common purpose; 
" Unlock managerial potential; and 
" Sustain the ability to manage growth. 
A financial goal of achieving RIO million synergy benefits in PresMed hospitals in 
the 2000 financial year was announced to industry analysts by the MD (Hogben, 
1999: 17). 
The outcomes of the implementation of the adapted integrated system in AHL 
hospitals resulted in significant margin improvements for the group, and curtailed 
the increase in costs of pharmaceutical and surgical consumables from 25% to 
less than 7% by September 1999 (Hogben, 1999: 15). As MD of Afrox Pharmacy 
Management Services (APMS), I identified the opportunity to implement the AHL 
integrated system in the recently acquired PresMed hospitals in order to meet the 
integration goals of the organisation and at the same time to independently test 
the adapted system from Cycle 2 in a completely new group of 19 hospitals. 
3.5.1 Progression of Cycle 3 
Figure 3.7 shows the progression of Cycle 3 through the action research steps 
using the input-process-output systems approach. 
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Figure 3.7: Graphic representation of the progression of Cycle 3 
The INPUT or REVIEW step in Cycle 3 involved the review of the existing system 
for the management of pharmaceutical and surgical consumable products in the 
group of 19 PresMed hospitals and the development of a plan for the 
implementation of the integrated system. 
The execution of the plan formed the ACTION or PROCESS phase of Cycle 3. As 
with Cycles 1 and 2, while these actions will be described progressively, 
implementation in the PresMed group of hospitals was not a single event, but 
rather a number of simultaneous actions across the hospitals. 
The outcomes of the implementation (OBSERVE or OUTCOMES components) 
were measured from October 1999 to September 2000, which represented a full 
financial year for the combined company. 
To ensure the change management process was followed, the adapted model, as 
discussed in Chapter 2, Figure 2.2: 25, was used to guide the approach. 
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3.5.2 Review of existing systems in PresMed hospitals 
In keeping with the methodology used in the first two (2) action research cycles, 
the input process began with identifying thematic concerns and group reflective 
questions based on a review of the existing system for the management of 
pharmaceutical and surgical consumable products in the newly acquired hospitals. 
The overall findings of this review showed that the outcomes of the existing 
system were significantly worse than those achieved in AHL, and the old-style 
buying function in PresMed was ill equipped to deal with risk-based re- 
imbursement tariffs. To develop an implementation plan a detailed review of each 
process was conducted. Tools from the AHL integrated system such as the 
formulary role map, change project description form and constituency analysis 
were used to customise the implementation plan for individual hospitals and 
address the concern of imposing an AHL system on the PresMed hospitals. 
A detailed gap analysis of each of the six (6) processes of the AHL integrated 
system was completed and action steps combined into an overall action plan. 
3.5.3 Implementation and change management 
The implementation process across the 19 acute-care PresMed hospitals followed 
the methods identified in Cycle 1 and adapted in Cycle 2 of the study. 
Implementation of each process was described in detail and their role and impact 
reviewed at the end of the Cycle. Throughout the implementation, change 
management processes as identified in the adapted model and described in the 
review of change management conducted in the input phase were considered and 
adopted as required. 
59 
3.5.4 Outcomes of Cycle 3 
The outcomes of implementation in the newly acquired hospitals were measured 
from the baseline of September 1999 to September 2000, which was the end of 
the financial year. 
" One (1) product selection process and information technology (IT) support 
system was used across all hospitals; 
" The value of pharmaceutical and surgical consumable products analysed for all 
hospitals reached 57%; 
" The percentage product reduction achieved through the product selection 
process was 68% for the combined group; 
" Products classified in the product database reached 83% from 67% at the end 
of Cycle 2 and the accuracy of data remained intact with the total value of 
products rejected into the suspense file at 5,6%; 
" The percentage product line compliance achieved was 80% in PresMed 
hospitals by the September 2000; and 
" All PresMed hospitals reached over 80% value compliance by that period and 
seven (7) hospitals had reached over 90% compliance, resulting in a total 
value compliance of 87%. 
To conclude the independent test of the system, I reviewed the application of the 
integrated system and its individual components. Table 3.5 shows a summary of 
each component of the integrated system in September 2000 compared to 
findings of the review conducted in September 1999, from which thematic 
concerns and the action plan were developed. 
60 
Table 3.5: PresMed hospitals: System in September 2000 compared to the 
review findings in September 1999 
FOCUS AREA REVIEW FINDINGS IN 
SEPTEMBER 1999 
PRESMED HOSPITALS BY SEPTEMBER 
2000 
1 PRODUCT " No product selection process " Integrated product selection process for 
SELECTION existed for either pharmaceutical both categories of products; 
PROCESS or surgical consumable " Classification system applied to all product 
products; analyses including product comparisons; 
" No classification system was in " Formalised system for product evaluation, 
place for product comparison; supplier evaluation and financial analysis 
" No formalised system for incorporated with AHL hospitals; 
product evaluation, supplier "A formulary for both pharmaceutical and 
evaluation or financial analysis surgical consumable products covering 
existed; 57% of all products (see Table 4.1 of this 
" Some standardisation of submission); and 
products had been embarked on " Supplier-only standardisation for 14% of 
and was communicated to products (see Table 4.1 of this 
pharmacy hospital staff through submission). 
workshops and by pharmacy 
operations managers in 
PresMed; and 
" No formulary was in place for 
either pharmaceutical products 
or surgical consumable 
products. 
2. IT SUPPORT " No information technology (IT) " Ability to utilise AHL information 
infrastructure existed to support technology (IT) systems to support the 
a product selection process or product selection process and 
the standardisation of products; standardisation of products; 
" No product utilisation database " Capability developed to incorporate data 
or centralised information on from multiple systems for product 
product purchases or usage utilisation review; 
information existed; " IT data analysis capability for both 
" There was no IT data analysis pharmaceutical and surgical consumable 
capability for these products; products; 
" There was no PresMed product " The price file was replaced with a full 
database. Hospitals leased the product database, which enables 
HHD price file except for one reporting, allows flagging of formulary and 
(1), which used an alternative non-formulary products and indicates 
file known as Comedis; and restrictions and classification of products; 
" Data on individual hospital " Data from individual hospitals could be 
product purchases was available retrieved from existing systems for all but 
in the hospital billing systems of one (1) hospital whilst all hospitals were 
which two (2) (ProClin and Delta moved to the MAC billing system; and 
9) were used in the group. " Access to formularies at hospital level was 
These were the equivalent of the in place for all hospitals that were moved 
MAC billing system used in AHL. to the MAC billing system. 
61 
FOCUS AREA REVIEW FINDINGS IN SEPTEMBER PRESMED HOSPITALS BY SEPTEMBER 
1999 2000 
3. FACTORS " As no formulary was in place for " Hospital implementation processes were 
IMPACTING either pharmaceutical or surgical in place, including sustained 
HOSPITAL consumable products the communication process to all 
IMPLEMEN- change management tools as stakeholders, agreed and aligned 
TATION described in Table 2.3 of performance measures and formulary 
PROCESS submission 2b had to be used; implementation teams; 
" No constituency analysis as " Constituency analysis completed for each 
described in Figure 3.6 of PresMed hospital and information to 
submission 2b existed; achieve doctor buy-in such as the doctor 
Procedures and protocols communication pack and decision support 
supported the existing limited material (DSM) available to all 
system of the management of pharmacists; and 
pharmaceutical and surgical " Monthly formulary newsletter provided to 
consumable products; and all pharmacy managers. 
" Doctors in PresMed had not 
been exposed to the concept of 
a formulary for pharmaceutical 
and surgical consumable 
products. 
4. MEASURE- " No formulary measurement and " Full spectrum of measurement and 
MENT AND management tools were in management tools for both pharmaceutical 
MANAGE- place. and surgical consumable products; and 
MENT TOOLS " Measures available at individual hospital 
level, for all PresMed hospitals and 
benchmark data for all hospitals including 
both PresMed and the original AHL 
hospitals. 
5. PHARMACY " Operational training and " Interpersonal skills training completed 
CAPABILITY development of pharmacy including conflict handling, negotiation 
DEVELOP- managers and pharmacists was skills and academic detailing; 
MENT through one-on-one contact with " Continuing medical education (CME) in 
pharmacy operations managers place to provide clinical and technical 
and regional workshops; knowledge for formulary implementation; 
" No specific skills development and 
training or clinical skills training " Ongoing formulary induction for new 
for pharmacy staff had been pharmacists. 
conducted in the last 5 years; 
and 
" There was some ongoing 
continued professional 
development undertaken by 
individual pharmacists through 
their professional hospital 
pharmacist association. 
6. SUPPLIER " Supplier relationships were " Supplier strategy and interface 
STRATEGY based on the buying function; incorporated into AHL integrated system: 
AND " Buying processes were not and 
INTERFACE formalised at centre; and " Supplier representative policy 
PROCESSES " No supplier representative policy implemented across all PresMed 
existed. All supplier hospitals. 
representatives had full access 
to market all products to all 
hospitals and departments. 
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The review showed that as a result of the implementation of the processes and 
sub-process, the newly acquired hospitals had transitioned from an old style 
procurement system to an integrated system for the management of 
pharmaceutical and surgical consumable products. I will now present the 
progressive outcomes of the three (3) action research cycles and discuss the 
overall impact of the integrated system. 
3.6 PROGRESSIVE OUTCOMES AND OVERALL IMPACT OF THE 
INTEGRATED SYSTEM 
Table 3.6 shows a summary of outcomes of each of the three (3) cycles including 
the comparison between the newly acquired hospitals (PresMed) and the existing 
hospitals (AHL) and the combined outcomes of all hospitals in the group at the end 
of Cycle 3. 
The results used for Cycle 2 are at the end of September 1999, which represents 
a further year of implementation and shows the developments to the beginning of 
Cycle 3. 
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Table 3.6: Summary of outcomes of Cycle 3: September 2000 
PROCESS MEASUREMENTS PRODUCT OUTCOMES 
CYCLE CYCLE CYCLE CYCLE CYCLE 
1 2 3 3 3 
Combined 
March 98 Sept 99 PresMed AHL AHL & 
hospitals hos itals PresMed 
Supplier-only Pharmaceuticals Not 14.5% 14% 
Process for standardisation measured 
product 
(4 2 1) 
_____ _________- _____(one 
process used for all hospitals) 
selection for 
Surgical consumable Not 14% 14% 
products measured 
pharmaceutical (one process_u sed fo ra II ho pitals) s 
and surgical TOTAL (All Not 14.5% _ __ _ _ _ _ 14% 
consumable products) measured 
products. (one process used for all hospitals) 
Value of Pharmaceuticals 37% 54% 74% 
pharmaceutical and (one process used for all hospitals) surgical consumable 
products analysed (% 
---------------------------- Surgical consumable 8% 40% ------------- 46% 
of group spend) products (one process used for all hospitals) 
(4.2.2) TOTAL (All 24% 52% ----------- 57% - 
products) one process used for all hospitals) 
Percentage reduction Pharmaceuticals 81% 85% 70% 
in number of products. (one rocess used for all hos hals (4,2 3) Surgical consumable 70% 63% 64% 
products (one process used for all hospitals 
TOTAL (AII 74% 68% 68% 
products) (one process used for all hospitals) 
Group Purchasing 
Information Information (GPI) - 6%(oct99) 
technology percentage of total TOTAL (All products) 13% 5% 
support 
value of products in 
the suspense file. 6% 5% 5 6% 
systems for the 4.3.1 , 
management of 
pharmaceutical 
PIPS database: Pharmaceuticals o 51 /0 0 70 /0 0 87 /o 
and surgical 
percentage of total 
value of products - 
one rocess used for all hos hals 1- 
consumable classified. Surgical consumable 15% 56% 79% 
products. (4.3.2) products (one process used for all hospitals) 
TOTAL (All 31% 67% 83% 
products) one process used for all hospitals) 
Pharmaceuticals 44% 68% 79% 84% 82% 
Hospital 
- ---------------- 
y 
Product line 
compliance. 
------------- 
Surgical consumable 52% 77% 81% 88% 85% 
Im plementation (4 4 1) products 
---- 
TOTAL (All 
---------- 
44% 
-------- 
75% 
-- 
80% 
-------- 
86% 84% 
products) (Phernraceui 
cats onl 
Not 89% 89% 92% 91% 
Product value Pharmaceuticals measured 
compliance. ------------- --------------- ------ 
(4.4 2) Surgical consumable Not 83% 86% 90% 89% 
products 
-- 
measured 
- -------------------------- 
TOTAL (All ----------------- Not 
----------------- 
87% 
----------------- 
87% 
------------------ 
93% 
------------------- 
90% 
products) measured 
3.6.1 Discussion of progressive outcomes 
The discussion of the progressive outcomes will follow the three (3) processes 
shown in Table 3.6. 
64 
3.6.1.1 Process for product selection 
One (1) process for product selection was used for all hospitals for both 
pharmaceutical and surgical consumable products across all three (3) action 
research cycles. Supplier-only standardisation was added in Cycle 2 in order to 
cover whole categories of products where a single supplier was selected but 
individual categories were not separated for single product selection (e. g. sutures). 
The 0,5% decrease in the percentage supplier-only-standardisation in Cycle 3 
represented the change in proportion of spend in the product categories for the 
combined organisation. The value of products analysed as a percentage of 
total spend on both types of products increased from 24% in Cycle 1, to 52% by 
September 1999 when the PresMed hospitals were acquired and reached 57% by 
the end of Cycle 3. This progress included the ongoing review of product selection. 
The percentage reduction in the number of products decreased from 74% in 
Cycle 1 to 68% in the next two (2) cycles due to some categories having fewer 
brand choices within them. 
3.6.1.2 Information technology (IT) support systems 
The same IT support systems were used for all hospitals in each cycle. The 
accuracy of information in the group purchasing information data base (GPI) 
was measured by the percentage of total value of products rejected into a 
suspense file. This value improved from 13% in Cycle 1 to a combined value of 
5,6% for all hospitals at the end of Cycle 3. Classification of products, which 
was a critical step in the product selection process, increased from 31% in Cycle 1 
to 83% for both pharmaceutical and surgical consumable products at the end of 
Cycle 3. The increase from 67% in Cycle 2 was due to an additional resource 
being added at the time of the PresMed acquisition to focus on accelerating the 
classification of products and increase product selection and review. 
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3.6.1.3 Hospital formulary implementation process 
Figure 3.8 shows the comparison of the percentage line and value compliance 
across the newly acquired PresMed hospitals and the existing AHL hospitals over 
the period September 1999 to September 2000. Both value and line compliance 
represents combined compliance for pharmaceutical and surgical consumable 
products. 
105 
95 
85 - 
65 
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35 
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99 00 
-a-- -PresMedvalue -AHL value - -"- -PresMed line J-AHL line 
Figure 3.8: Comparison of value and line compliance: September 1999 - 
2000 
Line value compliance increased from 44% in Cycle 1 to 84% by Cycle 3. This 
represents the progressive process of improvement of the integrated system and 
focuses on implementation and improvement as is built into the system, e. g. 
through the management and measurement tools such as the individual and group 
product compliance reports. In contrast to AHL hospitals in Cycle 1, the 
percentage line value compliance in PresMed hospitals exceeded the 70% target 
within three (3) months. Percentage value compliance reached 85% within 12 
months compared to 75% in AHL over the same period in previous cycles. This 
was attributed mainly to the fact that an already developed and improved system 
was rigorously implemented in PresMed rather than the draft system that was 
developed and implemented at the same time in AHL 
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3.6.2 Comparative outcomes for pharmaceutical and surgical consumable 
products 
Table 3.6 shows the differences in outcomes between pharmaceuticals and 
surgical consumables across all three (3) cycles. In all measures, except for 
product line compliance, outcomes were better for pharmaceutical products than 
they were for surgical consumable products. This is due to a number of factors, 
including: 
" No well-established product selection processes existed for surgical 
consumable products, either nationally or internationally, which means data on 
surgical consumables is less readily available; 
" The absence of regulatory processes for surgical consumable products 
resulted in an additional sub-process for surgical consumable products, namely 
the product trial process being added to ensure that quality criteria were met; 
and 
"A new classification system needed to be developed compared to using the 
established system for pharmaceuticals. 
The lower percentage reduction of products was due to the fact that it is more 
difficult to establish which products are the same as others, unlike with 
pharmaceuticals where active generic ingredients can be traced. The differences 
in value compliance were larger in the earlier cycles and improved in Cycle 3. This 
was due to the fact that the implementation of the integrated system was driven 
through the pharmacy department that were more familiar with pharmaceuticals 
and only improved their knowledge of these products over time. Each new surgical 
product also often requires a longer learning curve than for pharmaceuticals. 
3.6.3 Progressive impact of the integrated system 
The progressive impact of the integrated system determined the extent to which 
the business objectives were met. At the end of Cycle 1, the set target of 70% 
compliance was not met and only 24% of the total value of pharmaceutical and 
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surgical consumable products were covered by the product selection processes. 
As a result the targeted financial improvements for that period were not met, which 
resulted in the initiation of Cycle 2 to identify and address the gaps in the draft 
integrated system. 
In Cycle 2 it was recognised that the value of product spend covered by the 
integrated system was a better measure of the potential impact of the integrated 
system than the line items or units used. Through the various improved processes 
and new processes, resources and efforts were focused on improving the impact 
of the integrated system. 
A new measure was developed in Cycle 2. It provided a graphic representation of 
the percentage of total value compliance versus the percentage of total purchases 
covered in the product selection process. Both formulary products, where one (1) 
product and one (1) supplier was selected, and supplier-only standardisation, 
where a single supplier was selected for a category of products, is shown. 
Figure 3.9 shows the total value compliance percentage versus percentage of total 
spend covered by the formulary and supplier-only standardisation processes by 
September 1998. As shown in the graph, the total value of products covered by 
the product selection process increased to 52%, of which 39% resulted in a single 
product and single supplier for a category, and 13% in supplier-only 
standardisation. The percentage product value compliance reached 75.4% for 
formulary products and 77% for supplier-only standardisation. 
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100% 
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purchasing 
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compliance 
eye Formulary 
R105.3m 
Total purchases 
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and surgical 
consumable 
products = R270m 
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supplier-only standardisation= 52% 
Figure 3.9: Cycle 2: Total value compliance percentage versus percentage 
of total spend covered by the formulary and supplier-only 
standardisation processes: September 1998 
Importantly, despite the fact that the goal of 70% scope of products covered had 
not been reached because of the focus on high value products, the business 
results showed that the implementation of the integrated system exceeded the 
financial targets set. Financial improvement was demonstrated in the fee-for- 
service environment and cost-reductions were achieved in risk-based tariffs (AHL, 
1998). 
By September 1999, the value of products covered by the product selection 
process increased to 66.5%, with 52% single formulary products selected and 
14.5% supplier-only standardisation. In addition, the continued focus on high value 
items resulted in the product value compliance increasing to almost 87% by 
September 1999. 
A further improvement in margin in the fee-for-service environment and reduction 
in cost of products in risk-based tariffs was achieved in the financial year October 
1998 to September 1999 (AHL, 1999a). Overall, the adapted integrated system for 
pharmaceutical and surgical consumable products successfully curtailed the rate 
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of increase in the cost of pharmaceutical and surgical consumable products from 
as high as 25% in early 1998 to less than 7% by September 1999 (AHL, 1999b). 
Figure 3.10 shows data for the combined group, including AHL and PresMed 
hospitals by September 2000, at the end of Cycle 3. Supplier-only standardisation 
reduced to 14% of total spend when the two (2) groups were combined and 
represents the proportion of spend of the product categories, namely sutures and 
intravenous fluids. The percentage of products covered by the formulary increased 
from 52% in September 1999 to 57,4% in September 2000. 
100% Supplier-only 
standardisation 
90% 
General 
Purchasing 
Value Agreements 
Compliance Formulary 
R369m -., 
57.4% 
Total purchases 
for pharmaceutical 
and surgical 
consumable 
products = R643m 
100% 
% of Total spend covered by the formulary 
and supplier-only standardisation = 71% 
Figure 3.10: Cycle 3: Total value compliance percentage versus percentage 
of total spend covered by the formulary and supplier-only 
standardisation process by September 2000 
The ongoing review of existing categories is not represented in this figure, but 
continued to be a focus area throughout the period. The results shown in Figure 
3.10 reiterate the achievement of the targets set for the implementation of the 
integrated system, including total spend covered (target 70%) and value 
compliance (target 80%). Overall the outcomes showed that, as a result of the 
implementation of the integrated system for the management of pharmaceutical 
and surgical consumable products, the financial targets were achieved in both 
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PresMed and AHL hospitals, which in turn made a significant impact on the overall 
performance of the merged organisation (AHL, 2000). 
3.6.4 Impact of the supplier strategy 
The objective of the development and implementation of the integrated system 
was to maximise leverage opportunities and meet financial targets whilst ensuring 
no compromise in quality of care. Key to the ability to leverage the group was the 
impact of the supplier strategy in which the aim was to be able to shift market 
share across all hospitals. 
Figure 3.11 shows the impact of the application of the supplier strategy and formal 
interface as evidenced by the change in market share of a product across all 
hospitals in AHL from Cycle 2, when the supplier strategy was added to the 
system, through to the end of Cycle 3. 
Figure 3.11: Example of market share report for a surgical consumable 
product showing impact of PresMed hospital 
implementation 
As shown in the graph, the combined market share of the formulary product fell to 
below 70% when the PresMed hospitals were merged into AHL, but moved back 
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to over 90% with the formulary implementation process and through the work done 
jointly with the supplier. 
3.7 SUMMARY 
In this chapter I provided an overview of the three (3) action research cycles 
through which I determined what was needed to develop and implement an 
integrated system for the management of pharmaceutical and surgical 
consumable products. The outcomes of each cycle were summarised and a 
discussion of the progressive outcomes and impact of the integrated system over 
the three (3) cycles was presented. 
I will now describe the progression of the integrated system as derived from the 
deductive process following Karlsen's model. 
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CHAPTER 4 
PROGRESSION OF THE INTEGRATED SYSTEM OVER THE ACTION 
RESEARCH CYCLES 
4.1 Introduction 
4.2 Graphic representation 
of the integrated 
system 
4.3 Processes and sub- 
processes developed in 
the action research 
cycles 
4.4 Summary 
4.1 INTRODUCTION 
Figure 1.2: 14 showed a concept map 
of the study and differentiated 
between the objectives of the 
0 business project and the 
process linked to the research aim. 
action 
At the end of each action research cycle, as part of the independent contribution 
of the researcher, I reflected on the processes and outcomes of implementation 
and presented: 
"A diagrammatic overview of the integrated system; and 
"A summary of the features and key unique features of the integrated system 
compared to previous cycles. 
In this chapter, I will describe the progression of the integrated system over the 
action research cycles and present a final overview of the features and key 
unique features of the integrated system. This was used as the basis for the 
literature comparison conducted as the next step in the study. 
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4.2 GRAPHIC REPRESENTATION OF THE INTEGRATED SYSTEM 
In order to provide an overview of the integrated system, a graphic 
representation was presented at the end of Cycles 1 and 2 of the action research 
cycles. No changes were made in Cycle 3, as the aim was to independently test 
the existing system. 
4.2.1 Cycle 1: Draft integrated system 
Figure 4.1 contains a graphic representation of the draft integrated system for the 
management of pharmaceutical and surgical consumable products across all 
acute-care hospitals in AHL as defined by the end of Cycle 1. 
AFROX HEALTHCARE LIMITED (AHL) 41 
AFROX PHARMACY MANAGEMENT SERVICES (APMS) Hospital! 
H 
IT SUPPOR HOSPITAL PRODUCT 
SYSTEMS 
IMPLEMENTATION 
SELECTION PROCESS 
s 
Surgical 
PROCESS Consumables 
is 
Pharmaceuticals 
Oo 0 
TOOLS TOOLS TOOLS 
Eg Classification, Eg. Data E. g. Formulary 
Utilization Review 
warehouse 
hotline 
F MANAGEMENT & MEASUREMENT TOOLS 
RGICAL PHARMACEUTICAL 
CONSUMABLE PRODUCTS 
PRODUCTS 
Figure 4.1: Graphic representation of the draft integrated system for the 
management of pharmaceutical and surgical consumable 
products across all acute-care hospitals in AHL as defined in 
Cycle I 
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I will now explain the different components of the integrated system. 
The decision to include both 
SURGICAL PHARMACEUTICAL 
CONSUMABLE PRODUCTS 
PRODUCTS pharmaceutical and surgical 
consumable products into one (1) 
integrated system of management. This 
is depicted in the diagrammatic overview 
as green and yellow "integrated" shading. 
The four (4) processes of the draft 
integrated system, as identified, 
developed and implemented in Cycle 1, 
are shown as individual boxes, and tools 
developed within each of these contributed 
to the management and measurement 
tools process. The concept of using one 
(1) team and one (1) system of 
processes for all AHL hospitals that is 
managed through APMS is depicted in the 
dark blue shading. 
All hospitals in the group (purple boxes) as 
well as APMS as a centre of excellence 
are depicted as a system within the light 
blue box shown as AHL. This depicts the 
view taken of AHL as a system and the 
decision to develop the integrated system 
across all hospitals in order to maximise 
leverage opportunities. 
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Nrol °°o 
Surgical 
Consumables 
Pharmaceuticals 
The concept of a hospital as a system is 
represented in the diagram by the purple block and 
includes the integration of products into one (1) 
management system managed through the 
pharmacy department. Although doctors are 
independent practitioners, they are recognised as 
an integral part of the hospital system. 
4.2.2 Cycle 2: Adapted and enhanced integrated system 
Figure 4.2 contains a graphic representation of the improvements to the 
integrated system by the end of the second cycle. 
AFROX HEALTHCARE LIMITED (AHL) 
2 
AFROX PHARMACY MANAGEMENT SERVICES (APMS) 
NO 
"grow IT SUPPLIER HOSPITAL 
PRODUCT 
SUPPORT PHARMAC IMPLEMENTATION S 
SYSTEMS CAPABILI STRATEGY PROCESS SELECTION Surgical 
PROCESS Consumables is 
Pharmaceuticals 
ýoa 
TOOLS TOOLS 
TOOLS 
TOOLS TOOLS 
L 
MANAGEMENT & MEASUREMENT TOOLS 
SURGICAL PHARMACEUTICAL 
CONSUSLE PRODUCTS AFROX HEALTHCARE LIMITED (AHL) PRODUCTS 
I'KIVA It 
T 
C 
Z 
O 
m 
Figure 4.2: Graphic representation of the adapted integrated system as 
defined by the end of Cycle 2 
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The addition of the two (2) new 
processes in Cycle 2 is shown as two 
(2) further boxes. The inter-relationship 
of the processes is depicted by the 
overlap of the individual boxes. 
In addition, the inclusion of a supplier 
strategy resulted in the expansion of the 
context of the integrated system and the 
recognition of the integrated system 
as an open system. This is depicted in 
the addition of the green block around 
AHL, which includes the SA private 
healthcare environment, suppliers and 
funders as part of the system 
No changes were made to the system in Cycle 3. Instead, the application of each 
process was discussed and factors that affected achieved outcomes were 
highlighted. At the end of Cycle 3, all the processes and sub-process were fully 
implemented in the newly acquired hospitals. Economies of scale were realised 
from the utilisation of one (1) product selection team and the same processes, 
such as the information technology (IT) support systems, implementation 
systems, supplier strategy and pharmacy capability development across all 
hospitals. In addition, the implementation of an integrated system for both 
pharmaceutical and surgical consumable products was replicated in the new 
hospitals. 
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4.3 PROCESSES AND SUB-PROCESSES DEVELOPED IN THE ACTION 
RESEARCH CYCLES 
A summary of the purpose and key unique features of each of the individual 
processes and sub-processes of the integrated system was provided at the end 
of Cycle 1. In Cycle 2 improvements to the existing processes were presented, 
which included new processes and sub-processes in comparison with the 
previous cycle. 
Table 4.1 provides a summary of the processes and sub-processes of the 
adapted integrated system as developed in Cycles 1 and 2, as well as the 
independent test conducted in Cycle 3. 
Table 4.1: Processes and sub-processes of the integrated system for the 
management of pharmaceutical and surgical consumable 
products 
PROCESS OR SUB-PROCESS & 
PURPOSE 
FEATURES & KEY UNIQUE FEATURES 
PRODUCT SELECTION PROCESS Integrated system for both pharmaceutical and 
surgical consumable products; 
PURPOSE: Process for the selection of " One (1) process for all hospitals; 
pharmaceutical and surgical consumable " One (1) product selection team for all hospitals with 
products that results in a restricted relevant consultative participants brought in when 
pharmaceutical and surgical consumable required; 
formulary that: Formulary product review process; 
" Therapeutic substitution and formulary restrictions; 
" Has credibility with stakeholders; Formalised product and/or service complaint system 
" Leverages the group spend; and to provide feedback on quality of products and 
" Ensures optimal therapeutic outcome service levels of suppliers selected; and 
and quality of service. Supplier-only standardisation. 
1a. Classification system Integrated 7-tier classification system for 
pharmaceutical and surgical consumable products; 
PURPOSE: Provides a system for valid and 
comparison of products in the product selection Classification system for surgical consumable 
process and facilitates strategic analysis of products based on functional or therapeutic use. 
product usage. 
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PROCESS OR SUB-PROCESS & FEATURES & KEY UNIQUE FEATURES 
PURPOSE 
1 b. Prioritisation of product selection Utilisation review capability for both pharmaceutical 
process - product utilisation review and surgical consumable products; 
" Utilisation review for all product categories across all 
PURPOSE: Provides a system for the hospitals and per individual hospitals; and 
prioritisation of product selection and ensures a " Formulary product review criteria and processes. 
strategic approach to product selection. 
1 c. Clinical analysis process " A process for evaluation of surgical consumable 
products for use in AHL in the context of there being 
PURPOSE: To ensure efficacy and safety of no regulations in SA to evaluate these products; 
both pharmaceutical and surgical consumable One (1) clinical analysis team for all hospitals with 
products in the product selection process. relevant experts brought in when required; 
" Clinical analysis of new surgical products that 
includes a product trial process with involvement of 
users in hospitals; and 
" One (1) process for product review across all 
hospitals rather than multiple products being trailed 
at multiple hospitals. 
1d. Supplier evaluation process A national supplier evaluation across all hospitals 
that includes input from the hospitals and the 
PURPOSE: To ensure reliability and monitoring of service delivery; and 
consistency in supply across all hospitals. Formalised product and service complaint process 
to monitor suppliers. 
1e. Financial analysis A financial analysis process that covers both 
managed health care re-imbursement models and 
PURPOSE: To ensure cost-effectiveness of traditional fee-for-service. 
products and compliance with financial criteria. 
2. INFORMATION TECHNOLOGY (IT) Integrated IT system to support the management of 
SUPPORT SYSTEM both pharmaceutical and surgical consumable 
products; 
PURPOSE: To provide information One (1) IT system provides both a group and 
technology (IT) support for the integrated individual hospital perspective; and 
system for the management of Economies of scale across all hospitals enabled 
pharmaceutical and surgical consumable appointment of dedicated IT resources to ensure 
products. ongoing IT support and continuous improvement of 
IT capability for the integrated system. 
2a. Product utilisation database - " Combined utilisation data for all hospitals in terms of 
group purchasing information both pharmaceutical and surgical consumable 
(GPI) products; 
" Utilisation review capability across both categories 
PURPOSE: A system and process that provides of products to use in the product selection process 
ongoing, up-to-date information on product and to measure the impact of the 
integrated system; 
usage in individual hospitals and across all " Utilisation database that cross links to the product 
hospitals in the group. database and allows detailed analysis, e. g. by 
classification; and 
" Ability to include data drawn off non-AHL billing 
systems into the product utilisation database. 
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PROCESS OR SUB-PROCESS & FEATURES & KEY UNIQUE FEATURES 
PURPOSE 
2b. Product database One (1) integrated database for both pharmaceutical and 
surgical consumable products; 
PURPOSE: To provide a " Ability to hold multiple levels of information on all products; 
comprehensive interactive data " Can link to other systems, e. g. GPI, MAC billing system, etc.; 
storage capability that holds the full and 
range of products and has the ability to " Addition of therapeutic substitution and restrictions to 
carry additional key features for each database. 
product, e. g. formulary flags, 7-tiers of 
classification, etc. 
2c. Access to the formulary at Access to the formulary at hospital level with addition of 
hospital level information on therapeutic substitutions and restrictions on 
hospital billing and dispensing system. 
PURPOSE: To ensure pharmacy staff 
have access to the formulary at the 
time of dispensing and/or distribution of 
both pharmaceutical and surgical 
consumable products. 
3. HOSPITAL Pharmacy managers responsible for the implementation of 
IMPLEMENTATION both pharmaceutical and surgical consumable products; 
PROCESS Protocols and procedures in all hospitals aligned to deal with 
the integrated system; 
PURPOSE: To ensure effective " Formulary "hotline" established at centre to provide 
implementation of the integrated information and support for formulary implementation; 
system for the management of Doctor implementation through pharmacy managers; 
pharmaceutical and surgical Template for the development of a communication strategy 
consumable products across all and plan; 
hospitals in the group. Role map for hospital implementation; 
" Aligned performance management template; 
" Introduction of formulary implementation teams and training 
workbook; 
" Doctor constituency analysis method; 
" Communication pack for hospital and pharmacy managers to 
use for doctor buy-in; 
" Provision of decision support material (DSM) for all products 
to pharmacy staff; and 
" Monthly formulary newsletter with index for cross referencing. 
4. MEASUREMENT AND Measurement and management tools for both the progress of 
MANAGEMENT TOOLS the development of the system as well as the outcomes; 
" Measurement of outcomes in both categories of products 
PURPOSE: To ensure the effective across all hospitals and per individual hospitals; 
measurement and management of " Ability to use Cognos Impromtu0 and Cognos Powerplay® 
the integrated system for the tools in conjunction with the product database (PIPS) and 
management of pharmaceutical and group purchasing information (GPI) for detailed analysis; 
surgical consumable products New measure of value compliance for all products to add to 
across all hospitals in the group. line item compliance; 
" Scope of spend covered and value compliance to measure 
the progress of the implementation of the integrated system; 
and 
" Market share reports across all hospitals and per individual 
hospital for suppliers and to measure progress for analysed 
products. 
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PROCESS OR SUB-PROCESS & FEATURES & KEY UNIQUE FEATURES 
PURPOSE 
5. PHARMACY CAPABILITY Interpersonal skills training programme to support formulary 
DEVELOPMENT implementation, including: 
PURPOSE: To ensure that pharmacy 0 Conflict handling; 
managers and pharmacy staff have o Negotiation skills; and 
the necessary skills and knowledge 0 Academic detailing programme to train pharmacy staff to 
to effectively implement the interface with doctors on the same level as supplier 
formulary for both pharmaceuticals representatives "selling" the AHL formulary products. 
and surgical consumables across 
all hospitals in the group. Continuing Medical education (CME) modules aligned with 
formulary categories and designed to ensure clinical and 
technical knowledge for formulary implementation in terms of 
both pharmaceutical and surgical consumable products; and 
" Standardised formulary induction process for all hospitals to 
equip new pharmacy employees to implement the formulary 
for both pharmaceutical and surgical consumable products. 
6. SUPPLIER STRATEGY AND Supplier strategy and formalised interface process across 
FORMALISED INTERFACE both pharmaceutical and surgical consumable suppliers 
PROCESS incorporating the concept of approved suppliers, preferred 
suppliers, formulary suppliers and strategic partners; and 
PURPOSE: To ensure that the Formalised supplier interface for both pharmaceutical and 
supplier strategy and interface surgical consumable products, including: 
process support the system for the 0 
Standardised request for information and request for 
management of pharmaceutical and quotation documents in line with product selection 
surgical consumable products. process; and 
0 Supplier representative policy. 
4.4 SUMMARY 
In this chapter I provided a diagrammatic overview of the integrated system as it 
progressed over the three (3) action research cycles, and I presented a summary 
of the features and key unique features of the integrated system. 
The next step in the study was to return to the literature and review the individual 
components and the integrated system as a whole against the literature to further 
conceptualise the integrated system for the management of pharmaceutical and 
surgical consumable products. 
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As shown in Figure 4.3, this represented a further step of independent research 
and distinguishes the research aim from the business objectives. 
RESEARCHER 
CONCLUSION 
RESEARCH AIM 
Conceptualization 
INTEGRATED SYSTEM FOR THE and 
further 
MANAGEMENT OF literature 
PHARMACEUTICAL AND SURGICAL examination 
CUMABLE PRODUCTS 
AA GROUP OF PRIVATE 
ITALS 
PROJECT 
TEAM AND RESEARCHER 
BUSINESS OBJECTIVES 
-Maximise leverage opportunities 
-Financial targets met 
-Ensure quality and optimal 
therapeutic outcome 
Figure 4.3: Extract of overview of the study to distinguish the research aim 
from the business objective 
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CHAPTER 5 
COMPARISON TO INTERNATIONAL SYSTEMS THROUGH FURTHER 
LITERATURE EXAMINATION 
5.1 Introduction 
5.2 Research design and 
research methods 
5.3 Review of the concept of 
an integrated system 
5.4 Application of the 
systems thinking 
approach 
5.5 Improvements to the 
processes and sub- 
processes 
5.6 Further conceptualisation 
of the integrated system 
5.7 Summary 
5.1 INTRODUCTION 
The purpose of action research are 
twofold, namely to implement change 
and to generate theory (Greenwood, 
1994: 13 and Whyte, 1991: 54). As 
stated in Submission 1, the 
cornerstone of action research is 
based on the concept that knowledge 
r1 rivcrl from nrmrfirc mnrl fhnf nr-mntinc v -vI IVVJ 11 WI 11 1J1 uvllvV, 1I I%. l LI I UL '. JI Gvalvli 
informed by knowledge is an ongoing process (O'Brien, 1998: 6). 
An overview of the three (3) action research cycles of the study was presented in 
Chapter 3, and the progression of the development of the integrated system was 
described in Chapter 4. The next step in the study was to return to the literature to 
compare the integrated system with other systems of management for 
pharmaceutical and surgical consumable products, in order to: 
" Justify and understand the limitations of the integrated system; 
Highlight differences in the international approach; and 
Identify improvements and additions to the system from other studies. 
The literature examination covered the following key differences in the approach to 
the study: 
The development of an integrated system for the management of 
pharmaceutical and surgical consumable products (section 5.3); 
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" The application of systems thinking to the integrated system (section 5.4); as 
well as 
"A review of each of the processes and sub-process of the integrated system 
(section 5.5). 
After the completion of the above-mentioned steps, the learning derived from the 
literature examination was incorporated into a further conceptualisation of the 
integrated system (section 5.6). 
5.2 RESEARCH DESIGN AND RESEARCH METHODS 
The research question formulated for this step in the study was as follows: 
" Will the existing knowledge framework add to the development of a system for 
the management of pharmaceutical and surgical consumable products in AHL? 
An exploratory and descriptive design was applied where the results from the 
action research cycles and national and international literature served as the unit 
of analysis. Unlike the action research cycles, which followed a participatory action 
research method, this aspect of the study was conducted independently by myself 
(the researcher). 
The research methods utilised to achieve the objectives of Submission 3 included 
data collection, sampling and data analysis. 
5.2.1 Data collection 
The techniques of skimming, comprehending, analysing and synthesising, as 
described by Burns and Grove (2001: 129-130), were used for the extraction and 
utilisation of relevant information and content from the selected sources, to 
examine the existing processes and outcomes of the implementation of the 
integrated system against the literature. 
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5.2.2 Sampling 
Purposive sampling was used through the utilisation of key search words from 
national and international theoretical and empirical resources on the topic of 
systems of management for pharmaceutical and surgical consumable products. 
Specific searches were also done on the six (6) processes identified in the 
integrated system for the management of pharmaceutical and surgical 
consumable products, namely: 
" Process for product selection; 
" Information technology (IT) support systems for the integrated system; 
" Process for hospital implementation; 
" Measurement and management tools; 
" Pharmacy capability development; and 
" Supplier strategy and formalised interface. 
A further search was conducted on the concept of systems thinking as the 
generalised concept applied in the study. 
5.2.3 Data analysis 
Data analysis was done through content analysis using inductive reasoning and 
inductive generalisation. Derivation was also used as a strategy to analyse data, 
and entailed the redefinition and transposition of a concept, statement or theory 
from one (1) context to another (Mouton & Marais, 1992: 106). Concepts, 
statements and theories of the systems theory were transposed from the general 
theoretical framework and applied to the further conceptualisation of the integrated 
system within the operational framework of AHL (the contextual framework of the 
study). 
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5.3 REVIEW OF THE CONCEPT OF AN INTEGRATED SYSTEM 
No similar concept of combining the system of management for both 
pharmaceutical and surgical consumable products was evidenced in the literature, 
despite similar issues being recognised as found in AHL, such as the large 
numbers, increasing variety and duplication of surgical consumable products and 
the fact that both products impact on quality and costs of care. 
5.3.1 Pharmaceutical products 
There was ongoing evidence in the literature to support the concept of a 
management system for pharmaceutical products driven by the need to manage 
costs and ensure the use of high quality medicines. Compared to the literature 
review conducted as background to the study (see Chapter 1), the review 
conducted subsequent to the development and testing of the integrated system 
revealed that more studies had recognised the importance of the concept of 
medicine management systems as opposed to the compilation of a restricted list of 
drugs (Kahn, 2002: 159 and Fitzpatrick et al., 2001: 588). 
In addition, whilst earlier studies showed inconsistent outcomes pertaining to the 
implementation of a formulary, recent studies have indicated that hospitals that 
used the broader concept of medicine management systems have more 
consistently been able to demonstrate improvements in costs without 
compromising quality of care (Mullins et al., 2001: 71; Binyon & Cooke, 2000: 186 
and Fitzpatrick et al., 2001: 588). This was also the case with the integrated 
system. 
5.3.2 Surgical consumable products 
Recent literature has indicated that the need to adopt improved management 
systems in terms of surgical consumable products is increasingly being 
recognised. There is also an increasing realisation that traditional materials 
management solutions were insufficient to deal with risk-based reimbursements 
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such as per diem payments (HHNMAG 2002; Eskew, 2002: 24; Hoban, 2003: 28 
and Tambolas, 2004). This was also a key motivating factor for the integrated 
systems with per diem re-imbursement tariffs in AHL having increased to 40% of 
turnover in 2003 and was predicted to increase to over 70% by 2005 (AHL 2004) 
Factors impacting on the lack of progress with the management of surgical 
consumable products in other hospitals were identified and discussed, including: 
" The decentralised nature of materials management in hospitals; 
" Justification of old style procurement functions and systems through short term 
savings achievements; 
" Poor information availability for analysis and product selection; and 
" No way of comparing products due to the absence of a classification system. 
5.3.3 Rationale for integration 
Two (2) main common issues were highlighted as providing the rationale for the 
integration of pharmaceutical and surgical consumable products into one (1) 
system of management. The first motivating factor was that both types of products 
require a system to ensure quality of care through the rational use of products and 
avoidance of inferior products and those with potential serious adverse effects. 
Secondly both products contribute significantly to overall costs and require 
expenditure and costs to be controlled by recommending cheaper alternatives, 
competitive purchasing and avoidance of duplication. To further substantiate the 
decision to develop an integrated system, the following additional issues, as 
supported by the literature, were discussed: 
" Management of both product categories require co-operation with health 
professionals in order to ensure cost-effective quality care (Giaquinta, 1994: 30; 
Andrews, 2000: 16; Hoban, 2003: 29 and Neil, 2004: 3); 
" The opportunity exists to use the existing skills of pharmacists and the 
pharmaceutical formulary management processes based on the following 
factors: 
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o Pharmacists have a historical role as agents of change for promoting 
rational drug use (AI-Shaqha & Zairi, 2001: 284 and Stephens et al., 
2000: 256); 
o There is proven track record of successful pharmacist interventions to 
improve costs and quality of care in hospitals (Helling, 2000b: 577; 
Anderson 2002: 1163 and Dean et al., 2004: 201); and 
o Pharmacists have established credibility amongst healthcare professionals 
as providers of drug information (Lipton et al., 1995: 488); 
" Pharmacy departments have skills and management systems in place for the 
procurement, distribution and control of pharmaceutical products that could be 
extended to surgical consumable products (Samways, 2001: 144 and Al- 
Shaqha & Zairi, 2001: 284) 
" There is an increasing overlap in the usage of pharmaceutical and surgical 
consumable products. For example, medical administration devices and in-line 
filtration products have an impact on drug effectiveness and safety (ASHP, 
2002a and Schechter, 2004: S20); and 
" The importance of including both types of products in the development of step- 
care protocols and care pathways, which are increasingly being used to ensure 
cost-effectiveness and safety in the delivery of patient care (ASHP, 2004: 939). 
5.3.4 Benefits and limitations of an integrated system for AHL 
A number of benefits were realised from the development of the integrated system 
in AHL, for example: 
Ensuring that the impact on quality of care was properly considered in the 
selection criteria of both types of products; 
Using the same system of consultation with relevant health professionals for 
pharmaceutical product selection and surgical consumable product selection; 
" The efficiencies derived from using the infrastructure, management systems 
and existing skills of pharmacists for the management of both types of 
products; and 
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" The ability to holistically deal with surgical consumable products that have an 
impact on medication usage such as new drug-delivery devices. 
Limitations of the integrated system were divided into management system-related 
and pharmacy-related limitations. The two (2) main management system-related 
limitations identified were: 
" The fact that the integrated system was driven by a strong matrix function 
through APMS. The type of resources, infrastructure and executive 
sponsorship of APMS may not exist in other organisations; and 
" No formal materials management department existed in AHL hospitals or at 
head-office at the start of the study. The change management was therefore 
substantially less than for hospitals and hospital groups where it would be 
necessary to "merge" two (2) existing departments and/or move the 
management of certain products from a materials management department to 
the pharmacy department. 
Examples of pharmacy-related limitations identified included: 
" The impact of placing an additional burden of responsibility on pharmacy 
departments already facing staff shortages (Langleben, 2001: 470 and 
Anderson, 2002: 1165); 
" Distracting pharmacists from the core function of safe and effective 
medicine usage; and 
" The additional resources required to provide ongoing training for 
pharmacists in surgical consumable products. 
I will now summarise the findings from the literature of the application of the 
systems thinking approach. 
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5.4 APPLICATION OF THE SYSTEMS THINKING APPROACH 
A system is defined as a set of components that work together for the overall 
objective of the whole, a series of interrelated and interdependent parts, such that 
the interaction or interplay of any subsystem (parts) affects the whole (Bowditch & 
Buono 1997: 29, Cooper, 1997: 1 and Haines, 1998: 24). 
A comparison of the integrated system to the international approach resulted in the 
identification of key differences in the integrated system relating to the application 
of the systems thinking approach. Justification of each of the differences was 
provided based on a detailed review of the systems thinking literature. In addition 
limitations of the systems approach were highlighted and will be discussed in 
section 5.4.2. 
5.4.1 Differences and benefits of the systems thinking approach 
The key differences in the approach of the integrated system related to systems 
thinking and the benefits realised from this are summarised in Table 5.1. 
Table 5.1: Key differences and benefits in the systems thinking approach 
of the integrated system 
KEY DIFFERENCES IN THE 
APPROACH OF THE 
INTEGRATED SYSTEM 
RELATED TO SYSTEMS 
THINKING 
BENEFITS DERIVED FROM THE SYSTEMS THINKING 
APPROACH 
All hospitals in the group " The realisation of economies of scale and synergy benefits 
viewed as one (1) system and from the use of one (1) team and the development of one (1) 
the resultant process driven set of processes for all hospitals, both small and large; 
approach . The system was implemented across all hospitals at the 
same time, rather than following a fragmented approach of 
versus copying "best-practice" after a pilot study, thereby ensuring 
benefits flowed through to all hospitals which improved buy- 
Hospitals viewed as individual in; 
units and an activity or problem . The systems approach resulted in a focus on high value 
focused approach products across the group, thereby ensuring that the 
integrated system impacted on the financial performance of 
all hospitals; and 
" The group was able to impact on the market share of 
products across all hospitals and realise the resulting 
financial benefits. 
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KEY DIFFERENCES IN THE BENEFITS DERIVED FROM THE SYSTEMS THINKING 
APPROACH OF THE APPROACH 
INTEGRATED SYSTEM 
RELATED TO SYSTEMS 
THINKING 
A hospital viewed as a system " The systems approach enabled the development of a new 
with integrated boundaries and mental model relating to the management of surgical 
collaborative relationships consumable products, i. e. the opportunity to manage both 
products through the pharmacy department; and 
versus " Hospital implementation teams were able to see the larger 
picture and work together to meet performance targets. 
Different departments initiate 
separate activities resulting in a 
fragmented approach 
Integration of both types of " Ensured that the impact on quality of care was considered in 
products the management of both types of products; 
" Synergy derived from the ability to use the consultation 
versus process with health professionals for both types of products; 
" Efficiencies derived from using the infrastructure, 
Separate management of management systems to cover legislative requirements and 
pharmaceutical and surgical existing skills of pharmacists for both types of products; and 
consumable products " The ability to deal holistically with surgical consumable 
products that have an impact on medication usage, such as 
new drug delivery devices, thereby minimising the risk of 
medication errors as described in the example in section 
5.3.1 of this chapter. 
Adoption of the concept of " Leverage of spend and usage of both types of products 
leverage across the total group across all hospitals was made possible from the systems 
of hospitals and all products approach; 
" Resources and infrastructure such as IT resources could be 
Versus leveraged across all hospitals; 
" All hospitals were able to enjoy the same benefits by 
Individual hospital and separate leveraging the whole group that smaller hospitals would not 
departments limiting have been able to realise on their own; and 
opportunities for leverage " Shifting market share across all hospitals resulted in 
suppliers experiencing the leverage capability of the group 
and the co-ordinated implementation of the integrated 
system. 
Input-process-output model " The feedback loop of the input-process-output model 
provided the ongoing information required to be able to 
versus simultaneously develop and implement the integrated 
system; and 
Limited information flow across " The use of the input-process-output model also formed the 
departments and hospitals basis of a continuous improvement approach of the 
processes in the integrated system and ensured the system 
responds to both positive and negative feedback. 
The integrated system as an " Recognition of the integrated system as an open system 
open system ensured that there was an awareness and response to 
changes in the external environment such as mergers and 
versus acquisitions of suppliers, competitor activity and legislative 
changes. 
A problem-oriented analytical 
approach that tries to control 
individual departments as 
closed systems 
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5.4.2 Limitations of the systems approach 
The limitations identified in terms of the systems approach were discussed in 
detail in Submission 3, Chapter 4 and are summarised here as follows: 
" The size of AHL compared to larger organisations may prohibit all hospitals 
being regarded as a system and may impact on synergies that can be 
achieved. For example some authors have stated that larger healthcare 
organisations in the USA have shown little evidence of economies of scale 
(Goldsmith & Jeff, 1994: 26); 
" In AHL less than 40% of hospitals were greater than 200 beds. Smaller 
hospitals were able to benefit from combining all hospitals. In other 
organisations, larger hospitals may argue that they can leverage spend and 
realise synergies on their own; 
" SA has one (1) set of legislation governing medicines across all provinces. 
Different legislative processes in other countries were not considered, nor was 
the impact of having different legislation in individual states (such as in the 
USA). This may also impact on the scope of services that pharmacy 
departments may provide; 
" The development and implementation of the integrated system across all 
hospitals in AHL did not require the change process of disbanding existing PTC 
structures, as are in place in many other hospitals and hospital groups. The 
benefits derived for example from the economies of scale of one (1) system 
and one (1) product selection team across a group of hospitals where PTC 
structures already exists, would be limited by the complexity of the change 
management process to achieve this synergy; 
" The absence of a materials management department in AHL hospitals also 
resulted in an easier application of the concept of an integrated system for both 
pharmaceutical and surgical consumable products, i. e. it is easier to integrate a 
"turf" that is not being "defended"; and 
" Integrating surgical consumable products within the system may result in them 
not being considered when purchasing medical equipment that require these 
products as disposable attachments. This was overcome in the integrated 
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system by identifying the relevant products and establishing a consultative 
process that included the group clinical engineering department responsible for 
medical equipment. This was facilitated by the fact that this department also fell 
under my responsibility within the business, and may not be as easy to achieve 
where this is not the case. 
Further discussion on the limitations will be covered under focus areas for further 
research in Chapter 9. 
5.5 IMPROVEMENTS TO THE PROCESSES AND SUB-PROCESSES 
Each of the processes and sub-processes of the integrated system were reviewed 
against the literature in order to justify the process and make recommendations for 
further enhancements. The justification of each of the processes and sub- 
processes with supporting references was described in detail in Submission 3, 
Chapter 3. 
Overall, whilst concepts relating to the individual processes and sub-processes 
were evident in the management of pharmaceutical products in hospitals, there 
was no evidence of processes or a combination of processes being brought 
together as a functioning whole-system for the management of these products. 
I was also able to identify focus areas for further work within the processes and 
sub-processes in the more recent literature review. The recommendations for 
further work are summarised in Table 5.2. Only processes where enhancements 
were derived from the literature are included in the table. 
93 
Table 5.2: Recommendations for further work relating to the processes 
and/or sub-processes 
PROCESS OR SUB- RECOMMENDATIONS FOR FURTHER WORK DERIVED FROM 
PROCESS THE LITERATURE REVIEW 
1. PRODUCT Enhancement of a formalised product and/or service complaint 
SELECTION system is needed to ensure trends analysis across the group, the 
PROCESS classification of complaints and more feedback on trends rather than 
incidents, e. g. to suppliers. 
Clinical analysis "A formal decision matrix, as used by other systems, as described in 
process Submission 3, should be explored and the weighted assessment 
formally completed and kept on record; and 
" This should also be applied to the product trial process for new 
surgical products to ensure that the process is not simply an 
acceptance trial, but also explores local applicability of outcomes 
provided in international studies 
Financial "A greater use of pharmacoeconomic data has to be considered in 
analysis product selection as this data becomes available; 
" This concept needs to be extended to surgical consumable products 
and the group should use its leverage to ensure surgical suppliers 
increasingly undertake these studies; and 
" The Product Selection Team at APMS requires further training with 
regard to in pharmacoeconomic concepts and concepts relating to 
the total costs of surgical consumable products. 
2. INFORMATION " While some work was done to cross-link the IT support system with 
TECHNOLOGY (IT) procedures and diagnostic coding, further development is required 
SUPPORT SYSTEM to facilitate analysis of usage by procedures and diagnosis. This 
analysis will become important in risk-sharing tariffs and will need to 
include peer-review data as is found in large academic hospitals in 
the USA for example. 
3. HOSPITAL Implementation is not a once-off process, and, for example, 
IMPLEMENTATION formulary implementation teams must be sustained and trained on 
PROCESS an ongoing basis; 
" Communication processes must continue and must address gaps for 
new doctors and new staff; and 
" Protocols and procedures must be reviewed in light of ongoing 
changes. 
. PHARMACY " 
Competency assessments and evaluation of prior learning needs to 
CAPABILITY be built into both interpersonal skills training and continuing medical 
DEVELOP MENT education (CME); 
" Action learning projects in the individual hospitals will improve 
application of learning rather than theoretical learning in CME; 
" Interpersonal skills training and CME should be adapted and 
extended to nursing staff; and 
" Consideration should be given to register the training programmes 
with relevant professional bodies to ensure that health professionals 
meet their requirements for continuing professional development 
(CPD). 
SUPPLIER " The implementation of a more advanced supplier representative 
STRATEGY AND process as described in Submission 3, should be considered; and 
FORMALISED " As risk based reimbursement increases there will be a need to 
INTERFACE explore more ways to develop risk-sharing partnerships with 
PROCESS suppliers. 
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5.6 FURTHER CONCEPTUALISATION OF THE INTEGRATED SYSTEM 
Conceptualisation refers to the clarification and analysis of the key concepts in a 
study, as well as the way in which one's research is integrated into the body of 
existing theory and research (Mouton, 1998: 109). 
Two (2) adaptations of the diagrammatic overview of the integrated system were 
identified from the review of the literature, namely: 
To fully represent the integrated system following the literature review, I will now 
combine these two (2) concepts into one (1) and present a further version of the 
diagrammatic representation of the integrated system in Figure 5.1. 
In the first adaptation I recognised the importance of the ongoing feedback 
process to continuously review and improve the system. The continuous flow of 
information between a system, its internal components and the external 
environment forms a feedback loop that enables the organisation to adapt to 
changing conditions (Cooper, 1997: 2 and Bowditch & Buono, 1997: 19). The 
capacity to use this information to control the system and make necessary 
changes is crucial if organisations are to become self-correcting systems (Larsen 
et al, 1996: 13). As discussed in Section 4.6 of Submission 3, the input- 
transformation-output model together with the action research approach formed 
the basis of the development of the integrated system and allowed the 
simultaneous development and implementation of the system across all hospitals. 
The feedback loop in the form of outcomes of implementation provided the 
information from which I could adapt the system on an ongoing basis. 
This concept is built into the graphic representation of the integrated system by the 
inclusion of the input-process/throughput-output and feedback loop as applied to 
the processes and sub-processes of the integrated system. 
The second adaptation, described in Section 4.7 of Submission 3, is the addition 
of the orange block, which depicts the expanded environment of the open system. 
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Organisations are open systems that are influenced by a multitude of 
environmental forces or inputs such as availability of raw materials, changes in 
technology and government regulations (Haines, 1998: 17 and Cooper, 1997: 1). 
The integrated system operates as an open system and as such recognises that it 
is impacted by and impacts on the environment. Some examples of environmental 
forces impacting on the integrated system include legislative changes, the entry of 
new technology products into the market place, changes to suppliers in the form of 
mergers and acquisitions, competitor activity and public healthcare sector activity. 
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5.7 SUMMARY 
In this study I set out to develop and implement an integrated system for the 
management of pharmaceutical and surgical consumable products across a 
group of private hospitals. Through the three (3) action research cycles, the 
processes and sub-processes were identified, adapted and enhanced and then 
independently tested in a group of newly acquired hospitals. 
In order to highlight differences in the international approach; justify and 
understand the limitations of the integrated system and identify improvements 
and additions to the system, a further literature review was conducted and the 
findings were summarised in this chapter. 
An overview of the findings of the review were presented covering the following 
main themes: 
" The concept and rationale for an integrated system 
" The application of the systems thinking approach 
" Improvements and recommendations following the review of each of the 
processes and sub-processes. 
To conclude the chapter a further conceptualisation of the integrated system was 
presented from the concepts assimilated from the literature review. 
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CHAPTER 6 
APPLICATIONS AND OUTCOMES SINCE THE ACTION RESEARCH CYCLES 
6.1 Introduction 
6.2 Application of the integrated 
system to specialised 
products in cardiac 
catheterisation laboratories 
6.3 Implementation in a further 
group of hospitals known as 
Amahosp 
6.4 Outcomes across all 
hospitals: September 2000 to 
September 2003 
6.5 Lessons learnt from ongoing 
and more recent applications 
6.6 Summary 
6.1 INTRODUCTION 
The tight virtuous spirals of action 
research provide flexibility and 
responsiveness for effective change and 
also serve as substantiation of rigour 
(Zubber-Skerritt, 1995: 26 and Dick, 
2000: 72). 
In Chapter 3,1 presented an outline of the 
three (3) action research cycles that were used to develop, maintain and test the 
integrated system, and I also discussed and compared the outcomes of each of 
the cycles up to the end of September 2000. During the period September 2000 to 
September 2003 the study continued to progress as follows: 
A further cycle of action research was undertaken to extend the system to 
include specialised products in cardiac catheterisation laboratories; 
The integrated system was again implemented in a group of four (4) newly 
acquired hospitals known as the Amahosp group; and 
I continued to measure the outcomes of implementation of the integrated 
system across all hospitals. 
Each of these represents a further turn of the spiral of action research and 
provided yet another chance to substantiate the rigour of the study, which will now 
be discussed in turn. 
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6.2 APPLICATION OF THE INTEGRATED SYSTEM TO SPECIALISED 
PRODUCTS IN CARDIAC CATHETERISATION LABORATORIES 
In keeping with the business strategy to develop centres of excellence in 
specialised care, AHL developed specialised cardiac catheterisation laboratories 
(cathiabs) in four (4) of its large hospitals (AHL, 1998). The acquisition of the 
PresMed hospitals in September 1999 increased the number to five (5) and in 
October 2000 a 6th cathlab was opened (AHL, 2000). 
Because each of these units was established separately, there was little or no 
leverage of spend or synergy achieved. In addition, since the pharmaceutical and 
surgical consumable products used in cathlabs were specialised products, the 
implementation of the integrated system did not have a significant impact on these 
units. In November 2000 a further cycle of action research was undertaken to 
extend the integrated system to the six (6) cathlabs in AHL. The methodology 
followed that of the previous cycles. 
Since no new processes or sub-processes were added to the integrated system as 
a result of this cycle of research, I will only describe the application of the existing 
processes and summarise the outcomes achieved. 
6.2.1 Application of the processes and sub-processes of the integrated 
system to cardiac catheterisation laboratories 
Table 6.1 shows the application of the processes and sub-process of the 
integrated system to the six (6) cardiac catheterisation laboratories across AHL. 
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4. 
Table 6.1: Application of the processes and sub-processes of the 
integrated system for the management of pharmaceutical and 
surgical consumable products in cardiac catheterisation 
laboratories 
PROCESS OR SUB-PROCESS & APPLICATION IN CARDIAC CATHETERISATION 
PURPOSE LABORATORIES 
1. PRODUCT SELECTION PROCESS " As with previous cycles, I followed an integrated 
approach to the product selection process, including 
both pharmaceutical and surgical consumable 
products; 
" The existing product selection team was used with 
input from specialists in cardiac catheterisation 
(both doctors and nurses); and 
" Because of the specialised nature of the products 
the supplier-only standardisation process was 
selected. 
1a. Classification system " The integrated 7-tier classification system for 
pharmaceutical and surgical consumable products 
was extended to include specialised products used 
in cathlabs; and 
" The classification system for surgical consumable 
products used in cathlabs was also based on 
functional or therapeutic use. 
1b. Prioritisation of product "A product utilisation review was conducted using 
selection process - product data from the six (6) cathlabs; and 
utilisation review " The following product categories were identified as 
priorities: 
o Cardiac imaging products and intervention 
products (16 different suppliers were being 
used); and 
o Contrast media 5 different suppliers). 
1c. Clinical analysis process " The clinical analysis process was used to evaluate 
the products identified in the categories identified in 
1 b; and 
" Relevant cardiac catheterisation experts were 
included in the clinical analysis process. 
1d. Supplier evaluation process " The supplier analysis process was used and 
resulted in two (2) suppliers being identified for each 
of the categories identified in 1 b. 
1e. Financial analysis " The financial analysis process was used for the 
selection of the products and suppliers. 
2. INFORMATION TECHNOLOGY " The existing IT support systems were used. 
(IT) SUPPORT SYSTEM 
2a. Product utilisation database - " Combined utilisation data for all hospitals for both 
group purchasing information pharmaceutical and surgical consumable products; 
(GPI) and 
"I was able to utilise group purchasing data from all 
six (6) cathlabs in AHL for analysis and monitoring 
of progress. 
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VL 
PROCESS OR SUB-PROCESS & APPLICATION IN CARDIAC CATHETERISATION 
PURPOSE LABORATORIES 
2b. Product database " The classification of specialised cardiac 
catheterisation products was added to the product 
database and all relevant products linked to their 
respective classification. 
2c. Access to the formulary at " Access to formulary at hospital level was extended 
hospital level to include the cardiac catheterisation products. 
3. HOSPITAL IMPLEMENTATION Pharmacy managers were responsible for the 
PROCESS implementation of specialised cardiac 
catheterisation products, including both 
pharmaceutical and surgical consumable 
products; 
"A role map for cathlab implementation was 
developed; 
" Implementation teams that included strong 
representation by cardiac cathlab nurses were 
trained; 
"A detailed doctor constituency analysis was done 
for each of the six (6) cathlabs and used in the 
training of the teams; 
" Detailed communication plans were developed for 
doctor buy-in, including new decision support 
material (DSM); and 
" Monthly information sharing was instituted 
between all cathlab teams, including 
benchmarking data and information to support 
implementation. 
4. MEASUREMENT AND " Existing measurement and management tools 
MANAGEMENT TOOLS were used; 
" Additional information on cathlab activities were 
also collated and shared with staff in all six (6) 
cathlabs; and 
" Market share reports across all hospitals and per 
individual hospital were provided to suppliers 
where partnerships had been entered into. 
5. PHARMACY CAPABILITY Interpersonal skills training was reinforced to 
DEVELOPMENT support pharmacist responsible for implementation 
in cathlabs. 
6. SUPPLIER STRATEGY AND " Two (2) suppliers in each category of products 
FORMALISED INTERFACE were chosen as formulary suppliers; 
PROCESS " In the cardiac imaging and intervention category 
there was an undertaking to develop a strategic 
partnership starting with information sharing and a 
joint process to move market share from the 
existing 16 suppliers to the two (2) selected 
suppliers; and 
" The supplier representative policy in the integrated 
system was reinforced in the cathlabs. Specific 
obstacles were encountered with regard to 
representatives who provided technical assistance 
and were from non-selected suppliers. This was 
addressed through the implementation teams. 
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6.2.2 Outcomes of the application of the integrated system in cardiac 
catheterisation laboratories 
The outcomes of the application of the integrated system in cardiac catheterisation 
laboratories are presented in Table 6.2. Compliance in this table refers to 
compliance to the use of the two (2) selected suppliers for each category of 
products. In all cases the price of products from the selected suppliers marked a 
significant improvement, which resulted in improved financial performance in the 
cardiac catheterisation laboratories across the group. 
Table 6.2: Outcomes of the application of the integrated system in cardiac 
catheterisation laboratories across the group 
ontrast eia 
Compliance 
Diagnostics 
Compliance 
Cardiac Intervention 
Compliance 
CATHLAB Nov-00 Sep-03 Nov-00 Sep-03 Nov-00 Sep-03 
1 90 94 46 93 26 55 
2 77 100 21 93 43 59 
3 75 97 26 87 29 63 
4 90 97 32 88 45 87 
5 90 99 30 80 35 84 
6 80 70 65 91 70 79 
Compliance for the cardiac intervention products was the most difficult to achieve 
and sustain. The rapid technology innovations by suppliers and new suppliers 
entering the market with new products, required ongoing effort in the product 
review process. Because of the specialised nature of these units, doctor buy-in 
requires ongoing effort and the implementation team needs to ensure rigorous 
monitoring and interventions. Any lapse on behalf of the cathlab team resulted in a 
non-selected supplier product being used and a decrease in compliance as shown 
in the contrast media in cathlab 6. This was mostly due to staff changes, either in 
the pharmacy or the nursing staff in the cathlab. In addition, the ongoing need to 
keep up to date with advances in technology resulted in it being more difficult to 
apply the supplier representative policy and non-formulary suppliers used 
supposed technology advances, to change product usage. 
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6.2.3 Conclusion 
Despite the specialised nature of the cardiac catheterisation laboratories, the 
outcomes of this cycle of research showed that the integrated system for the 
management of pharmaceutical and surgical consumable products could be 
applied to specialised units, and with consistent effort, the benefits in terms of 
synergy and leverage could be achieved. 
Specific challenges are however experienced in these units, especially those 
relating to the ability to respond to ongoing technological changes. For example, a 
high level of interaction is required with specialist doctors in order to differentiate 
between those product technology changes that are actual advances, and those 
with limited or no additional benefits. 
6.3 IMPLEMENTATION IN A FURTHER GROUP OF HOSPITALS KNOWN AS 
AMAHOSP 
In January 2002, AHL acquired a group of four (4) hospitals in Kwazulu Natal 
known as the Amahosp group. As with the PresMed acquisition, the incorporation 
of the newly acquired hospitals was achieved swiftly (Flemming, 2002: 15). 
The incorporation of the four (4) hospitals into the AHL group included the 
implementation of the integrated system for the management of pharmaceutical 
and surgical consumable products. Implementation followed the same process as 
described in Submission 2c in terms of PresMed hospitals, and will therefore not 
be described in this submission. 
Outcomes for the four (4) hospitals will be included in the outcomes across all 
hospitals (see section 6.4) from March 2002. 
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6.4 OUTCOMES ACROSS ALL HOSPITALS: SEPTEMBER 2000 TO 
SEPTEMBER 2003 
In addition to the application of the integrated system to cardiac catheterisation 
laboratories and the implementation in the four (4) Amahosp hospitals, all 
processes within the system, including the formulary review process, continued to 
operate across all hospitals. 
Because of the focus on the value impact of the integrated system, I will limit the 
presentation of outcomes achieved to value compliance as a measure rather than 
line-item compliance. 
Figure 6.1 shows the formulary value compliance across all hospitals in the AHL 
group over the financial years October 2000 to September 2003. 
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Figure 6.1: Formulary value compliance across all hospitals in AHL showing 
the total compliance as well as individual pharmaceutical and 
surgical consumable product value compliance: October 2000 - 
September 2003 
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Formulary compliance for both pharmaceutical and surgical consumable was 
sustained over the next three (3) financial years. The following factors affected 
compliance: 
" The decrease in surgical consumable product value compliance during March 
and April 2001 was due to the change of a product during the formulary review 
process; 
" The decrease in formulary value compliance across the group during March 
and April 2002 represents the implementation of the integrated system in the 
four (4) Amahosp hospitals that were acquired in January 2002; and 
" The decrease in surgical consumable product value compliance during 
September and October 2002 was due to a stock-out following the September 
11 disaster in the USA. 
Table 6.3 shows individual hospital value compliance at the end of each financial 
year from September 2001 to September 2003. 
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Table 6.3: Individual hospital formulary value compliance at the end of the 
financial years: September 2001,2002 and 2003 
Sep-01 Se 02 Sep-03 
HOSPITAL 
Pharmaceutical 
products 
Surgical 
products Combined 
Pharmaceutical 
products 
Surgical 
products Combined 
Pharmaceutical 
products 
Surgical 
products Combined 
1 96.7 91.9 94. 967 92.0 94.0 93.9 98.1 95. 
2 92.2 90.0 91. 943 92.8 93. 98.9 92.7 96.1 
3 95.4 96.7 96. 98.1 94.4 96.4 98.6 94.8 96. 
4 97.6 92.2 95. 98.2 96.3 97.3 96.1 96.4 96. 
5 95.6 93.0 94. 93.9 93.0 93.4 93.9 92.5 93. 
6 86.8 91.6 89. 92.3 95.7 93. 98.6 94.2 96. 
7 98.0 97.2 97.7 90.5 93.3 91.6 94.3 94.6 94. 
8 94.0 941 94.1 89.6 78.3 84. 93.7 97.1 95.2 
9 92.3 97.9 94. 95.0 96.6 95.8 98.4 98.8 98. 
10 96.5 96.8 96. 96.3 93.7 95.1 95.3 93.1 95.01 
11 95.6 88.7 93.1 95.8 87.2 91.7 99.8 98.6 99. 
12 97.8 90.0 94. 98.4 91.4 94. 98.4 95.9 97.1 
13 89.5 94.4 91. 93.6 92.3 93.0 95.8 94.9 95. 
14 66.9 96.4 75. 70.0 95.6 78.2 70.2 95.7 78. 
15 88.9 84.9 86. 98.5 89.2 94.2 95.8 95.9 95. 
16 96.7 942 95.7 959 92.3 94.3 93.4 96.9 94. 
17 96.1 92.1 94. 96.8 88.4 92.4 98.9 94.2 96. 
18 94.2 97.5 95. 97.3 94.0 95.8 99.8 100.0 99. 
19 95.7 93.3 94.7 90.1 93.7 91.7 95.2 94.3 94.81 
20 89.9 87.2 88.7 93.2 77.8 85.6 98.6 94.1 96. 
21 95.5 86.9 91. 97.1 92.2 95.2 99.0 97.6 98. 
22 94.8 93.0 94. 96.9 92.4 94. 93.5 97.6 95. 
23 100.0 88.3 94. 96.7 83.8 90. 90.8 89.7 90. 
24 96.8 85.6 93. 98.0 86.0 92. 97.4 90.7 94.61 
25 89.9 70.1 81. 89.4 58.8 76. 98.1 97.1 97. 
26 99.4 99.9 99. 84.3 87.3 85. 98.0 95.5 96. 
27 93.2 98.3 95. 92.6 93.8 93. 99.4 93.4 97.1 
28 96.1 90.3 93.41 95.7 90.2 93. 98.4 90.3 95. 
29 95.0 91.2 93. 95.2 93.5 94. 87.0 66.4 77. 
30 95.7 97.3 96. 96.6 93.0 95.31 95.5 99.3 97. 
31 99.9 97.2 98. 98.9 99.2 99.1 98.1 97.3 97. 
32 98.2 94.7 96. 97.7 93.1 95.31 97.6 97.9 97. 
33 92.0 90.8 91. 96.6 87.8 91.5 1 97.9 93.1 95. 
34 94.2 99.9 94. 96.3 81.0 96.0 1 98.0 92.5 95. 
35 99.0 91.4 95. 99.2 98.7 99. 96.9 98.1 97. 
36 99,4 100.0 99. 97.6 96.6 97. 100.0 99.1 99. 
37 97.9 95.5 96. 97.1 87.7 93.2 97.7 92.0 94. 
38 87.9 90.7 89. 97.5 92.2 94. 98.0 93.2 95. 
39 98.4 95.0 96. 96.0 760 86. 98.7 100.0 98. 
40 94.3 85.9 90. 95.8 85.8 91.1 97.4 99.2 98. 
41 96.2 78.5 92.1 98.4 87.7 92. 97.4 99.9 98. 
42 94.4 83.7 89. 95.7 86.4 91.3 1 98.0 91.5 94. 
43 92.4 79.0 88. 93.5 85.1 90.0 1 96.5 84.7 91. 
44 72.1 78.0 87. 98.3 99.6 98. 
45 83.8 96.5 90. 94.4 93.5 93. 
46 88.6 87.4 88.1 99.6 96.0 97. 
47 87.3 93.0 89. 96.8 92.5 95. 
TOTAL 94.5 92.4 93. 94.9 88.6 92. 97.0 94.7 95. 
Results for the four (4) Amahosp hospitals (numbers 44 to 47) are shown as of 
September 2002 and 2003. Individual hospitals achieved a consistent 
improvement over time. Changes in any month were investigated and corrective 
actions implemented. In most cases these changes were a result of staff changes 
or unmanaged supplier representative activity. When a general decrease in 
compliance occurred it was mostly due to product changes from the formulary 
review process and occasionally due to supply problems that were subsequently 
addressed. 
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Figure 6.2 shows the total value compliance percentage versus percentage of total 
spend covered by the formulary and supplier-only standardisation process by 
September 2003. 
100% 
Value 
Compliance 
0/0 
Total purchases 
for pharmaceutical 
and surgical 
consumable 
products = 
R1,7billion 
100% 
Figure 6.2: Total value compliance percentage versus percentage of total 
spend covered by the formulary and supplier-only 
standardisation process: September 2003 
The total spend on pharmaceutical and surgical consumable products reached 
R1,7 billion by September 2003, which reflected the continued growth and 
acquisition strategy in AHL. The supplier-only standardisation in this graph 
includes application in the cardiac catheterisation laboratories where formulary 
suppliers were selected. The decrease in the percentage of the supplier-only 
standardisation represents a change in product mix due to the acquisition of new 
hospitals. 
Overall the integrated system covered almost 70% of the value of product spend 
and of that 95% of the value of purchases across all hospitals complied with the 
selected formulary product and/or formulary supplier. 
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4 --111- 
% of Total spend covered by the formulary 
and supplier-only standardisation = 67.6% 
6.5 LESSONS LEARNT FROM ONGOING AND MORE RECENT 
APPLICATIONS 
The ongoing and more recent applications of the integrated system had a number 
of challenges that can be highlighted as lessons learnt, namely: 
" The processes and sub-process in the integrated system are dynamic and all 
of them need to be applied with discipline and rigour or the system as a whole 
would be compromised. For example, delays in the review of products or 
rushing through a surgical product trail can (and did) create dissatisfaction 
amongst staff and doctors, which then threatened their confidence in the 
system; 
" Doctor and staff buy-in are critical both to effective implementation and to 
ongoing application. Complacency, taking things for granted and deciding to 
skip steps are the greatest risks in this regard. New doctors and new staff need 
to be effectively inducted and new staff trained in the relevant skills. The doctor 
constituency analysis tool must to be used properly and must also be updated 
on a regular basis. Decision support data and training material had to be 
updated to ensure that the credibility of product choices is maintained; 
" The communication plan for all relevant stakeholders must be updated 
regularly. New ways of presenting data and creative ways of maintaining 
awareness and interest have to be developed to re-energise commitment to 
the integrated system; and 
" The results from the ongoing measurement and monitoring within the 
integrated system must be reviewed with discipline and corrective actions must 
be implemented with regard to non-compliance. 
Overall, the risks related to the further and ongoing application of the integrated 
system revolved around the temptation to leave out components of the system, 
take shortcuts and the failure to utilise the tools developed in the action research 
cycles. In the study, each time this occurred, I was able to take corrective action 
by going back to ensure the rigorous and disciplined application of the processes, 
sub-processes and tools in the integrated system. 
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6.6 SUMMARY 
In this chapter I described and discussed the applications and outcomes of the 
study during the period September 2000 to September 2003. 
The first application was to implement the integrated system in cardiac 
catheterisation laboratories (cathlabs) as a further cycle of action research. The 
outcomes showed that the processes and sub-processes of the integrated system 
could be applied to both pharmaceutical and surgical consumable products, 
including specialised products in cathlabs across AHL with resulting financial 
benefits. A higher level of interaction and interventions with specialists in cathlabs 
is however required to sustain synergies. 
The second application was to implement the integrated system in four (4) hospital 
acquisitions known as the Amahosp group. Implementation followed the process 
of Cycle 3, as summarised in Chapter 3, and the outcomes were consistent with 
previous implementations in new hospitals. 
Finally the integrated system continued to operate across all hospitals in AHL. 
Outcomes showed continuous improvement consistent with the input-process- 
output and ongoing feedback systems approach. Lessons learnt were highlighted 
and revolved around the discipline and rigour in the application of all the 
processes, sub-processes and tools within the integrated system. 
I will now reflect on the business objectives of the project. 
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CHAPTER 7 
REFLECTIONS OF THE BUSINESS OBJECTIVES 
7.1 Introduction 
7.2 Business objectives 
7.3 Integrating the 
management of both 
types of products 
7.4 The impact of following 
a systems approach 
across all hospitals 
7.5 Summary of overall 
business impact 
7.1 INTRODUCTION 
I used action research as the generic 
research paradigm of the study because the 
emphasis was on the implementation of 
change across all hospitals, while at the 
same time ensuring that the aim of 
developing an integrated system for the management of pharmaceutical and 
surgical consumable products was achieved. As a result, I was both project leader 
of the business project and researcher the study, and throughout the study I 
emphasised the need to achieve both the business objectives and research aim as 
illustrated in the concept map contained in Figure 1.2: 14. 
In this chapter I will reflect on the business objectives and summarise the impact 
of the integrated system on AHL. 
7.2 BUSINESS OBJECTIVES 
The starting point of the study was the achievement of a critical mass from the 
acquisition of six (6) new hospitals and a subsequent strategic planning session in 
which existing practices for the management of pharmaceutical and surgical 
consumable products were reviewed, with a view to addressing the question of 
how to make the whole greater than the sum of its parts. 
The motivation for the study in AHL was summarised in Chapter 1, and the goals 
of the project arising from the strategic planning session were stated as follows: 
To identify synergy opportunities and leverage the total group spend in 
pharmaceutical and surgical consumable products; 
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" To develop the capability of managing product selection and usage for both 
types of products by pharmacists, nurses and doctors across all AHL hospitals; 
and 
" To manage and support the implementation of this process to meet financial 
targets, maximise leverage opportunities while at the same time maintaining 
quality of care. 
In addition, the following three (3) driving forces arose from the external factors: 
" The expected increase in risk-based, managed healthcare reimbursement 
systems for hospitals; 
" The continued impact of the rising medical inflation of pharmaceutical and 
surgical consumable products on both the affordability of healthcare and profit 
margins in hospitals; and 
" The threat of future legislation to control the cost of medicines in the private 
sector. 
I will now discuss the impact of the decisions made during the project and the 
study on AHL. 
7.3 INTEGRATING THE MANAGEMENT OF BOTH TYPES OF PRODUCTS 
Arising out of the goal to identify synergy opportunities was the decision to develop 
an integrated system for both pharmaceutical and surgical consumable products. 
Table 7.1 shows the business reasons for the decision to integrate the two (2) 
types of products at the start of the project and summarises the outcomes and 
impact of the decision at the end of the study. 
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Table 7.1: Business reasons for the integration of the two (2) types of 
products and the outcomes and impact thereof 
RATING THE TWO (2) TYPES OF 
" Surgical consumable products 
represented a high percentage of 
turnover in the fee-for-service 
environment and costs in the risk- 
sharing reimbursement tariffs in AHL. 
In order to achieve economies of 
scale, I set out to use the resources, 
expertise and infrastructure across 
both groups of products. 
A quality assessment process was 
needed for surgical consumable 
products to address the lack of 
regulatory requirements in SA. 
To ensure that the total cost of 
products used in patient care was 
evaluated in the product selection 
process, and where appropriate, the 
product selection processes of the two 
(2) types of products could be 
combined. 
The absence of regulatory 
requirements resulted in a 
proliferation of similar surgical 
consumable products entering the 
market, which presented an 
opportunity for a reduction in the 
number of products used. 
I hypothesised that a system to 
establish doctor acceptance of the 
rationalisation and standardisation of 
pharmaceutical products could be 
used to achieve the same objective 
with doctors and nurses in terms of 
surgical consumable products. 
OUTCOMES AND IMPACT 
By September 2003 surgical consumable 
products represented 51% of the combined 
spend and 24% of total group turnover and 
continued to have a significant impact on 
overall costs in risk-sharing reimbursement 
tariffs. The improvement in financial 
performance was proportional to the ratio of 
spend on these products. Failure to include 
these products in the system would have 
resulted in this proportion of spend and 
turnover being unmanaged. In contrast to this, 
significant cost and margin benefits were 
realised by applying the system to both types 
of products. 
The use of resources such as the information 
technology (IT) infrastructure, product 
selection process and hospital 
implementation process for both products, 
delivered the economies of scale as was set 
The quality assessment processes used 
internationally for pharmaceutical products 
was also used for surgical consumable 
products. In addition a product trial process 
was introduced in the integrated system for 
these products to further meet the quality 
objective for surgical consumable products. 
The use of one (1) product selection team 
and an integrated approach to product 
selection ensured that a holistic perspective 
was used for product selection and where 
surgical consumables impacted on 
pharmaceutical products the selection 
process was combined. Examples were 
provided in the study. 
The identified potential reduction in surgical 
consumable products was realised. A 64% 
reduction in the number of products was 
achieved with considerable financial impact 
on costs. 
The hypothesis using the same system to 
achieve doctor and nurse acceptance of the 
rationalisation and standardisation of surgical 
consumable products was validated by the 
compliance levels achieved and the financial 
benefits realised as summarised in Chapter 3. 
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Subsequent to the action research cycles, the application of the integrated system 
to specialised cardiac catheterisation laboratories (cathlabs) showed that with 
sustained effort, combining the two (2) types of products into one (1) system could 
also be applied in more specialised environments. The impact on AHL was a 
substantial reduction in costs of products in cathlabs and a further contribution to 
the improved financial performance (AHL, 2003b). 
7.4 THE IMPACT OF FOLLOWING A SYSTEMS APPROACH ACROSS 
ALL HOSPITALS 
To maximise leverage opportunities and meet financial targets the decision was 
made to follow a systems approach, and develop and implement the integrated 
system across all hospitals in AHL hospitals at the same time. This contrasted with 
the alternative option which was to pilot a system in one (1) hospital and then 
attempt to replicate it in the remaining hospitals over time. 
To achieve this objective, a change management methodology was combined with 
the action research approach. The decision was vindicated by the results achieved 
for the group as a whole, as well as and per individual hospitals. The outcomes in 
individual hospitals were similar across hospitals and the combined effect resulted 
in significant changes in market share for products that was leveraged in order to 
realise the financial benefits (Figure 3.11: 71). 
By the end of the action research cycles, the six (6) processes within the 
integrated system were established and implemented across the group. No lapses 
in quality were experienced during the process due to the quality assessment 
process that was built into the product selection process, and the ongoing 
monitoring and feedback system that was established. The feedback system was 
enhanced by the inclusion of all hospitals in the system and differentiated local 
issues from genuine quality non-conformances. The ability to share benchmark 
data across all hospitals also contributed to the achievement of the financial 
targets as each hospital set out to reach "best in class" performance. 
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In terms of financial impact, replicating the implementation of the integrated 
system across the group of 19 newly acquired PresMed hospitals also resulted in 
the achievement of over R8 million savings. Following the three (3) action 
research cycles the integrated system was also implemented across a further 
group of four (4) hospitals acquired in 2002, known as the Amahosp group. The 
impact of the implementation included both a margin improvement and an 
improvement in costs in risk-based reimbursement tariffs in this group (AHL 
2003a). 
7.5 SUMMARY OF OVERALL BUSINESS IMPACT 
As a result of the development and implementation of the integrated system for the 
management of pharmaceutical and surgical consumable products, the total group 
spend on both products was leveraged to achieve improved financial results in 
both the traditional fee-for-service environment and in risk-based reimbursement 
tariffs in AHL (AHL, 1999; 2000; 2001; 2002). 
Margin improvement for both categories of products in the fee-for-service 
environment improved significantly while AHL remained the lowest cost provider in 
the private healthcare industry (AHL, 2003b). Risk-based reimbursement tariffs, 
such as per diem and fixed fee tariffs, increased to over 40% of turnover by 
January 2003. Improved costs of pharmaceutical and surgical consumable 
products contributed to both risk management and good financial performance in 
this component of the business. (AHL, 2002 and AHL, 2003a). 
In response to the external factors identified: 
" The expected increase in risk-based, managed healthcare reimbursement 
systems for hospitals had come to fruition and is expected to increase further 
in 2004/5 (AHL, 2004). As described above, the integrated system has 
significantly impacted on cost and risk management in this form of 
reimbursement; 
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" The integrated system contributed to the reduction in medical inflation of 
pharmaceutical and surgical consumable products and AHL had positioned 
itself as the lowest cost provider in the industry; and 
" Legislation to control the cost of medicines in the private sector was 
promulgated in 2004, forcing other major private hospital groups to move to 
risk-based reimbursement systems. The integrated system provided AHL with 
a competitive advantage to deal with the legislative changes by ensuring that a 
system is in place across all hospitals to manage product usage and spend. 
Overall, from a business perspective, the integrated system has delivered the 
objectives of the project, namely to: 
" Maximise leverage opportunities; 
" Meet financial targets; and 
" Ensure quality and optimal therapeutic outcome. 
In terms of the research objective, I will now reflect on the progression of the 
integrated system for the management of pharmaceutical and surgical 
consumable products across a group of hospitals as summarised in Chapter 4. 
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CHAPTER 8 
FURTHER PROGRESSION OF THE INTEGRATED SYSTEM 
8.1 Introduction 
8.2 Adaptation of 
Haines's systems 
approach to strategic 
planning and 
management 
8.3 Graphic 
representation and 
description of the 
further progression 
8.4 Benefits of the 
further progression 
of the integrated 
system 
8.5 Summary 
8.1 INTRODUCTION 
The progression of the integrated system 
over the three (3) action research cycles 
was presented in Chapter 4 and further 
conceptualised and improved as shown in 
Figure 5.1: 97, following the review of the 
literature and comparison with international 
systems. 
As stated by Reid and Koljonen (2000: 4), organisational and customer needs are 
not static but are dynamic and change continually. As a result, a company's output 
and/or processes may be considered innovative today, but, may as a result of 
competitive forces and other environmental forces, be rendered commonplace or 
obsolete tomorrow (Flood, 1995: 44). 
In the integrated system, as presented in Figure 5.1: 97, the input-transformation- 
output model is applied to the individual processes, the hospitals and the system 
as a whole and provides an ongoing mechanism for the continuous improvement 
of the integrated system. 
However, whilst the concept of ongoing feedback ensures that the processes and 
sub-process are continuously updated and adapted based on the feedback 
mechanism, it does not provide a structured process to ensure that the integrated 
system is adapted to respond to the changes in the environment and the 
healthcare market. 
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In order to address this, I adopted concepts from the systems model used by 
Haines for strategic planning and management and as a result developed a further 
progression of the integrated system as will be discussed next. 
8.2 ADAPTATION OF HAINES'S SYSTEMS APPROACH TO STRATEGIC 
PLANNING AND MANAGEMENT 
Haines (2000: 10) stated that planning and change are the primary responsibilities 
of management and leadership. He defined an organisation's strategic decision- 
making as a process driven by feedback mechanisms through which an 
organisation's managers try to monitor its internal conditions and aspects of its 
external environment, to direct and regulate the organisation's efforts and thereby 
adapt the organisation to a changing environment. Similarly, the progression of the 
integrated system introduces a further dimension and structured approach through 
which the management and leadership of AHL, and its pharmacy management 
company APMS, can adapt to the rapidly changing healthcare environment. 
Haines's method differs from traditional planning methods, which start by 
analysing today's issues, problem-solve those issues and then conduct long-range 
forecasting and planning by projecting into the future (Booyens, 2001: 73). In his 
approach, and the approach adopted in the integrated system, a systems 
approach is used that focuses on the outcomes and then looks at ways to bridge 
the gap between the present and the required outcomes. The basis of the 
approach is the established systems model of input, process/throughput, output 
and feedback. However, in Haines's model a fifth element, namely environment, is 
added and, as stated earlier in this paragraph, the order is changed to start with 
output rather than input as shown in Figure 8.1. As such, the approach 
emphasises and studies the organisation as a whole and its interaction with the 
environment. 
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C. INPUT D. PROCESSITHROUGHPUT _ A. OUTPUT E . ENVIRONMENT 
ýý B. FEEDBACK 
Figure 8.1: Haines's basic systems model: Five (5) key elements of systems 
thinking from theory to practice (Haines, 2000: 37) 
8.3 GRAPHIC REPRESENTATION AND DESCRIPTION OF THE FURTHER 
PROGRESSION 
To further progress the integrated system, I used Haines's steps and systems 
approach to strategic planning and management (Haines, 2000: 29) and 
incorporated them into the graphic representation of the integrated system as 
shown in Figure 8.2. 
In Table 8.1 each of the key steps as numbered in the diagram is summarised and 
the application thereof to the integrated system described. 
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Table 8.1: Application of Haines's systems approach to strategic planning 
and management in respect of the integrated system 
(Adapted from Haines 
DESIRED STATE 
SHARED FUTURE GOALS 
2 
The process begins with the identification 
of a desired state and the establishment 
of shared future goals. The vision must 
be supported by desired outputs and 
results that are measurable and aligned 
with creating customer value. Generally 
requires a three (3) to five (5) year view. 
ENVIRONMENTAL SCAN 
There are two (2) points that require one 
to observe and act on environmental 
changes. The first requires the 
formulation of a view of the future 
environment on which the shared future 
goals were based. 
The second environmental scan is a 
review of the current environment during 
the current state assessment shown as 
step four (4). It includes a competitor 
analysis, market orientation, market share 
and growth rate, an analysis of customer 
needs and other relevant concepts. 
Feedback is assessed against 
measurable goals set on a year-to-year 
basis. 
In this step the desired future goals for the 
management of pharmaceutical and surgical 
consumable products across all hospital in 
AHL were identified. 
The vision was supported by desired outputs 
such as financial targets, percentage 
compliance required and other measurement 
and management outcomes as developed in 
the integrated system. 
Since the integrated system is an open 
system, the first environmental scan involves 
the formulation of a view of the future external 
environment which will impact on AHL. This 
includes the components illustrated in the 
graphic representation of the system such as 
legislation, expected changes in the private 
healthcare market, changes relating to 
suppliers and funders, as well as general 
social and economic factors. 
The second scan of the environment looks at a 
current state assessment and will be 
discussed in step 4. It would include, for 
example, the extent to which AHL has entered 
into risk-based reimbursement tariffs with 
funders, any further acquisitions and growth of 
AHL, etc. 
Feedback from the existing integrated system 
within AHL is obtained through quantifiable 
outcome measures within each of the 
processes, as well as the overall results in 
terms of leverage, quality and financial impact. 
A decrease in compliance, for example, would 
require a review of hospital implementation 
and possibly other processes such as 
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DESCRIPTION APPLICATION IN THE INTEGRATED 
(Adapted from Haines, 2000) SYSTEM 
4 CURRENT STATE ASSESMENT Internally each of the processes within the 
integrated system must be reviewed and 
The current state assessment requires an consideration given as to whether they are still 
honest assessment of where one is today needed, must be adapted and/or whether 
versus the ideal future vision. It is used to others must be added. This is over and above 
determine how much energy, time and the ongoing parallel process feedback system 
what resources are needed to get from that is monitored on a monthly basis. 
where one is today to reach the desired 
state as defined in the shared future goal. An annual SWOT analysis will ensure that 
strengths are harnessed and opportunities 
This includes an internal assessment as identified for inclusion in the annual plan. For 
well as an external assessment as example, the ability to shift market share from 
described in the environmental scan (2). one (1) supplier to another can be applied to 
It requires one to take a step back into further categories of products to increase 
the bigger picture. Techniques such as an scope. 
analysis of strengths, weaknesses, 
opportunities and threats (SWOT) can be The weaknesses and threats should be 
used with a corresponding list of action identified, e. g. the effectiveness of the supplier 
implications for each. representative policy, and mitigating actions 
included in the annual plan. 
ANNUAL STRATEGY REVIEW In the integrated system, the overall strategies 
and action items must be identified to bridge 
The annual strategy review is the step in the gap between the current state assessment 
which the core strategies and action and the future vision. For example, these may 
items that will bridge the gap between the include extending the integrated system to 
ideal future vision and the current state further specialised products, adapting to 
assessment is developed. legislation, addressing identified risks in risk- 
based tariffs, etc. 
The result is three (3) to seven (7) core 
strategies, which, when put into practice In addition, each of the processes must be 
across the organisation, become the reviewed and adapted to ensure that the 
primary means to your desired end, the desired state is achieved through the 
desired state identified in step one (1). implementation of strategic action items. Both 
Each core strategy should have overall strategies and strategic actions related 
corresponding strategic action items to the processes must be prioritised over the 
prioritised over the next 12 months. next 12 months. 
Buy-in of the organisation must be Buy-in of the organisation is ensured through 
ensured through parallel processes the continued collaboration and consultation 
conducted with relevant stakeholders. with key stakeholders as identified in the 
communication plan that is included in the 
hospital implementation process. 
BUSINESS ALIGNMENT Importantly, the integrated system does not 
operate in isolation within AHL, but must be 
In this step each core strategy is aligned with the overall business strategy. 
assessed to determine if any are outside 
the overall business strategy. Input into this step is obtained during the 
current state assessment. Issues that need to 
be considered include AHL's growth strategy, 
changes in tariffs, the impact of other projects 
and initiatives in the business, technology 
changes in the group, etc. 
Alignment with the financial expectations for 
the management of pharmaceutical and 
surgical consumable products is also assessed 
in this step. 
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DESCRIPTION APPLICATION IN THE INTEGRATED 
(Adapted from Haines, 2000) SYSTEM 
7 ANNUAL PLAN The development of the annual plan involves 
the process of sharing and prioritising. Sharing 
The development of the annual plan of strategies across departments, individual 
involves the process of sharing and hospitals and employees, enables the 
prioritising and includes sharing of development of supportive planning across 
strategies across departments departments and all hospitals rather than 
separate strategies. 
Alignment of hospital and departmental 
budgets, as well as individual planning and 
performance measures related to the priorities 
for the integrated system, are completed in this 
step. 
ONGOING STRATEGY The importance of the change management 
IMPLEMENTATION AND CHANGE methodology was highlighted in the three (3) 
MANAGEMENT action research cycles of the study. The 
implementation of strategy related to the 
In this step plans are put into action and integrated system requires an ongoing change 
are tracked, monitored and adjusted as management approach. 
necessary. 
A number of tools were identified in the 
integrated system, such as the role map, 
constituency analysis and communication plan, 
which ensured an ongoing review of key 
stakeholders. The continued use of these tools, 
as well as the adoption of others as needed, is 
important to ensure effective change 
management and strategy implementation. 
9 PROCESSES AND SUB-PROCESS Step nine (9) involves aligning the processes 
OF THE INTEGRATED SYSTEM and sub-processes of the integrated system 
with the core strategies and annual plans. It 
This step is an added step in the model ensures that actions required to adapt and/or 
and ensures a review of the processes maintain the processes and sub-process are 
and sub-processes in order to align implemented across all hospitals in line with 
these with the annual plans. these strategies. 
As described in step three (3), there is also an 
ongoing parallel feedback process, which 
ensures that the integrated system can be 
adapted based on the monthly measurement of 
outcomes for both individual hospitals and the 
organisation as a whole. 
10 OUTPUT Measurement of the outcomes of the 
integrated system occurs monthly and is also 
The measurement of the actual output reviewed as part of the annual strategic review 
completes the system cycle and also process. 
begins it again. It identifies the extent to 
which the desired state has been The availability of measurable outcomes for 
achieved and is the start of the annual each hospital and for the group as a whole is 
strategy review, assessment and an important component of the feedback 
feedback. Both positive and negative process in the integrated system. 
outcomes provide the essential 
ingredients for feedback, issues 
identification and renewal. 
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8.4 BENEFITS OF THE FURTHER PROGRESSION OF THE INTEGRATED 
SYSTEM 
The key benefit of the further progression of the integrated system is the provision 
of a systematic process and structure for the ongoing review of the system. This is 
important to ensure that the principle of continuous improvement is applied to the 
system as a whole, as well as to the individual processes and sub-processes. 
Whilst the integrated system is a system in itself, it is also a sub-system of the 
larger system of AHL as a whole and the overall healthcare system in SA. The 
further progression provides a macro-process to ensure that the integrated system 
is adapted and enhanced in response to the ongoing changes in the healthcare 
environment. 
In addition, through the inclusion of Haines's step 6, the alignment of the 
integrated system with the overall business strategy of AHL is facilitated. This has 
the additional benefit of ensuring ongoing executive management support for the 
integrated system. 
The progression also provides a structured approach for exploring transferability to 
other contexts such as the South African public sector and possibly hospitals in 
other countries. This will be discussed further in Chapter 9 as focus areas for 
further research. 
8.5 SUMMARY 
In this chapter the further progression of the integrated system, adapted from 
Haines's systems approach to strategic planning is described and presented 
graphically. The application of each step is explained within the context of the 
integrated system and the benefits of the further progression discussed. 
I will now reflect on the innovations of the study and focus areas for further 
research. 
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CHAPTER 9 
INNOVATIONS AND FOCUS AREAS FOR FURTHER RESEARCH 
9.1 Introduction 
9.2 Innovations 
9.3 Further impact of 
the achievement of 
the business 
objectives 
9.4 Focus areas for 
further research 
9.5 Final conclusion 
9.1 INTRODUCTION 
In this study the aim was to develop an 
integrated system for the management of 
pharmaceutical and surgical consumable 
products across a group of private hospitals. 
As research practitioner in this study, I set out to develop new perspectives and 
bring new thinking to the opportunity/problems presented and thereby contribute to 
wider learning. At the same time, by combining research with business practice, I 
aimed to act on the new perspectives and ideas and test them in practice. 
To meet these objectives I used an action research paradigm that included a 
participative collaborative process as well as independent critical review and 
conceptualisation by myself (the researcher). 
The overall concept map of the study was presented in Figure 1.2: 14. By the end 
of the action research cycles and further comparison to international systems, the 
overall aim to develop an integrated system for the management of 
pharmaceutical and surgical consumable products across a group of private 
hospitals was achieved. Further applications and outcomes of the system were 
described and reflections of the business objectives showed that the business 
outcomes for AHL were realised. 
In order to provide a structured approach and systematic process for the 
integrated system to respond to changes in the environment, including the 
healthcare market, a further progression of the integrated system was developed 
based on Haines's (1998) systems approach to strategic planning and 
management. 
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In this concluding chapter of the Innovation Report I will summarise the 
innovations and discuss focus areas for further research. 
9.2 INNOVATIONS 
"Innovative outcomes are generally the result of a creative thinking process that 
entails recognising gaps and missing elements, formulating hypotheses, revising 
and retesting these hypotheses and sharing the results with the interested 
community. Regardless of their forms these innovative outcomes must have value 
and demonstrate newness through combining and recombining of known 
elements" (Khalil, 1996: 32). 
In the "creative thinking process" that initiated this study, I recognised a gap in the 
management of pharmaceutical and surgical consumable products in light of the 
health industry changes, and in particular the introduction of risk-based 
reimbursement tariffs such as per diem and fixed fee tariffs. In addition the growth 
in the organisation presented the opportunity to maximise leverage and realise 
synergy through the management of these products across all hospitals in the 
group. 
Through the three (3) cycles of action research, hypotheses were formulated, 
revised and retested and outcomes shared. The main innovations that were 
initiated by this research project were: 
" The development of an integrated system for the management of both 
pharmaceutical and surgical consumable products; and 
" The systems approach that resulted in all hospitals in the group being regarded 
as a single system, i. e. the development of an integrated system across all 
hospitals in the group. 
In both of these innovations "value" was demonstrated: 
" In the impact on the financial performance as described in Chapter 7; 
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9 In the ability to extend the integrated system developed in the study to further 
newly acquired hospitals as described in Chapter 6; 
" In the sustainability of the outcomes over a prolonged period as indicated in 
Chapter 6; and 
" In the implementation of processes that ensured the use of quality products 
across the group of hospitals. 
Other innovations and key unique features in the integrated system were initiated 
within the framework of the main innovations, and will be highlighted in the 
discussion of each of these. 
9.2.1 Integration of both pharmaceutical and surgical consumable products 
The decision to develop one (1) integrated system for the management of both 
pharmaceutical and surgical consumable products was successfully carried out in 
the study and resulted in significant synergies through the use, for example, of one 
(1) product selection process, one (1) information technology (IT) system and a 
single approach to hospital implementation. No other systems of management that 
integrated these two (2) types of products were evident in the literature review 
conducted before and after the action research cycles. 
As a result of this innovation a number of other innovations and key unique 
features were developed within the integrated system, which will now be 
described. 
9.2.1.1 Surgical consumables classification system 
Whilst international classification systems exist for pharmaceutical products no 
equivalent system was available for surgical consumable products. As a result, a 
surgical classification system based on functional therapeutic use was developed 
as a sub-process of the product selection process within the integrated system. 
The 7-tier classification system remains a competitive advantage to AHL, as it is 
the critical requirement for a product selection process for these products and is 
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also used as the basis for data and trend analysis. The absence of a classification 
system for surgical consumable products was identified in the literature review as 
an important factor limiting the development of management systems for these 
products. 
9.2.1.2 Utilisation review capability for both products 
Drug utilisation review (DUR) is an important component of management systems 
for pharmaceuticals (ASHP, 2000: 137). The integration of both products into one 
(1) system, including the use of one (1) information technology (IT) system and 
database, resulted in utilisation review capability for pharmaceutical and surgical 
consumable products. This enables the management of the total cost of products 
in AHL of which surgical consumable products constitute 51 % of combined spend 
and 24% of total turnover in the group. The ability to review and manage both 
types of products is critical in risk-based reimbursement tariffs, which increased 
from 5% at the start of the study to 40% at the end of the action research cycles 
and is expected to reach over 70% by 2005 (AHL, 2004). Whilst the high cost of 
surgical consumables was increasingly recognised in the literature review, 
management systems for these products were impeded by the lack of information 
and the absence of utilisation review capability. 
9.2.1.3 Pharmacy departments responsible for management of both types of 
products 
As a result of the decision to develop an integrated system for management of 
both types of products, pharmacy departments were given responsibility for all 
aspects of the management of surgical consumable products and were the key 
drivers of the hospital implementation process in each individual hospital. The 
result of this was the ability to utilise the skills of pharmacists in medicines 
management, drug information and interaction with healthcare professionals for 
both types of products. In addition the benefits of procurement, distribution and 
control is applied to surgical products, which increasingly have the same 
regulatory and safety requirements as pharmaceutical products. 
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9.2.1.4 The application of a formal quality assessment to surgical consumable 
products 
Unlike the strict quality assessment processes applied to pharmaceutical products 
through the regulatory processes required for registration, there are no regulatory 
requirements for surgical consumable products in SA. The implementation of the 
integrated system resulted in a quality assessment process being applied to 
surgical consumable products. This was a first formal process in the South African 
private healthcare market. 
9.2.2 The development of an integrated system across all hospitals 
The decision to develop a single integrated system across all hospitals in the 
group was the second main innovation of the study. This was motivated by the 
objective to maximise synergy and the opportunity to leverage the spend of all 
products used across all hospitals. Unlike other international management 
systems that used individual committee structures in each hospital, the integrated 
system used one (1) product selection team across all hospitals and one (1) 
system of measurement that provided both individual hospital data and overall 
group data. Amongst others the benefits of this innovation included: 
" The ability to move the market share of a product across all hospitals resulted 
in a corresponding financial leverage capability; 
" The efficiencies realised as a result of resources being shared across all 
hospitals, e. g. product selection team, research data requirements, information 
technology (IT) infrastructure, training material development costs, etc.; and 
" Small and medium size hospitals realised leverage benefits that could not be 
achieved on their own. 
As with the decision to use one (1) system for both products, the decision to use 
one (1) system for all hospitals resulted in further key unique features within the 
integrated system. 
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9.2.2.1 Utilisation review across all hospitals 
As a result of the decision to develop one (1) system across all hospitals, the 
technological development of measurement and management tools were also 
designed to cater both for multiple individual hospitals and to consolidate data for 
group purposes. AHL is considered to be the only private hospital group in SA that 
is able to accomplish this accurately (AHL, 2003b: 7). The ability to consolidate 
data and provide utilisation review for the group as a whole ensured a focus on 
products that achieve high impact on the performance of AHL. In addition, 
progress can be monitored in individual hospitals and across all hospitals and is 
used in the supplier partnership process to identify gaps and develop action steps. 
Internal benchmarks are produced monthly and provide each hospital with a view 
of what is achievable at other hospitals. 
The availability of data for all hospitals in a common database linked to 
classification and more recently to diagnosis and treatment codes, is also 
regarded as unique in the South African private healthcare sector and has 
positioned AHL as a leader in the availability of information and analysis capability 
for further risk management in risk-based reimbursement tariffs (AHL, 2003b: 4). 
9.2.2.2 Market share shift of products across the group 
The ability to demonstrate the effectiveness of the integrated system in shifting 
market share of individual products is important in terms of leverage capability. 
This is especially important, because AHL represents over 30% of the private 
hospital market and a shift of product market share across all hospitals has a 
significant impact compared to changes in market share in isolated hospitals. The 
types of changes in market share and leverage realised as a result would not have 
been realised without the inclusion of all hospitals in the group. The fact the 
system operates as a whole also ensures that this process and leverage can be 
repeated with new products or opportunities without having to get each hospital to 
co-operate in terms of product by product. 
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9.2.2.3 Tools in the hospital implementation process 
To balance the view of all hospitals as a group with effective implementation at 
individual hospitals that responds to local issues, tools such as the Doctor 
Constituency Analysis and Role Map Application Tool were adapted from existing 
change management tools and are used as needed during implementation. Whilst 
these concepts are common in change management literature, adaptations to the 
needs of the integrated system, and the incorporation thereof into the 
management system as a whole, are unique in SA and were not evident in the 
literature review of management systems for these products. 
9.3 FURTHER IMPACT OF THE ACHIEVEMENT OF THE BUSINESS 
OBJECTIVES 
As stated in chapter 1, in this study I chose not to use the conventional business 
approach of reengineering, but rather to connect business practice and research. 
In doing so, I not only brought new perspectives and thinking to the problems and 
opportunities but also acted on the new ideas and tested them out in practice. 
Throughout the study I emphasised my role as both research practitioner and 
project leader of the business project. In Section 7.5 I summarised the overall 
impact of achieving the business objectives of maximising leverage opportunities 
and meeting financial targets whilst maintaining quality and therapeutic outcomes. 
The ongoing application of the integrated system has resulted in a further 2% 
reduction in the overall cost of pharmaceutical and surgical consumable products 
across the group over the period October 2003 to September 2004 (AHL, 2004b). 
The total spend on these products was over R1,5 billion for this period. 
In addition, the ongoing application of the integrated system has had further 
impact on practice resulting from the achievement of the business objectives for 
the study. Examples of these include: 
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" The entrenchment of the concept of leverage; 
" An ongoing collaborative approach across different disciplines and hospitals 
to organisational challenges and opportunities 
" The systems approach of a hospital viewed as a system 
9.3.1 The entrenchment of the concept of leverage 
The successful implementation and results from applying the concept of leverage 
in the development of the integrated system have resulted in the concept being 
entrenched within the organisation. In addition the realisation that we can make 
the whole greater than the individual parts and how we do this, have been 
extended to other business practices. This has largely been due to the impact of 
the successful implementation of the integrated system across all hospitals 
through action research, in contrast to utilising more traditional methods of a pilot 
study followed by a roll-out to individual units. 
An example of the further application of the concept of leverage is the 
development of a group wide virtual warehouse of pharmaceutical and surgical 
consumable stock. In this application, near expiry or underutilised stock from all 
hospitals is stored electronically in a data warehouse and is accessible to all 
pharmacy departments as well as the group pharmacy management department. 
This facilitates a consolidated approach to discussions with suppliers on the return 
of underutilised stock and ensures that hospitals that use products more frequently 
use up stock that would expire if it remained on the shelf in another (often smaller) 
hospital. The application also leverages off the data warehouse capability 
developed as part of the integrated system. The impact of this further application 
has been a significant decrease in stock written off that has decreased from over 
5% to less than 3% of total stock within 12 months, an estimated saving of R2,7 
million (AHL, 2004b). 
As a result of the buy-in to the concept of leverage arising from the success 
demonstrated in the integrated system, individual hospital management teams and 
the executive management of the organisation are now willing to support other 
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opportunities that were regarded as too specialised. This includes leveraging the 
group spend in the procurement and maintenance of medical equipment, so that 
both large and small hospitals benefit. A recent application in anaesthetic machine 
replacement and maintenance has resulted in a further 15% saving on what was 
already regarded as preferential prices. Many of the processes from the integrated 
system were applied in ensuring that all 65 hospitals participated in the 
opportunity. This included the role map application, doctor constituency analysis 
and communication tools. 
9.3.2 Ongoing collaborative approach 
As a result of the collaborative approach to the implementation of the integrated 
system within the hospitals, different departments have applied the concept of 
working together to tackle other organisational challenges and opportunities. 
The success of formulary implementation teams was recently emulated by the 
finance department. The delay in documentation and collation of the patient 
account had resulted in debtors' targets and organisational cash flow being 
negatively impacted. A project based on the collaboration of the nursing 
department and pharmacy department with the administration department was 
implemented in each hospital and replicated across the organisation. The result of 
this collaborative team approach, both within and between hospitals, has ensured 
that overall the group has decreased the time to deliver a final bill from up to 9 
days at the start of the project to less than 4 days. This has had a positive impact 
on the debtors' target which has reached an all time best. The concept of targeted 
actions which have high impact, as used in the integrated system in the formulary 
compliance reports, was also utilized in this initiative. This allowed the 
collaborative team to focus on high impact changes rather than work through 
previously lengthy reports. In addition each department was able to focus on their 
role in implementing the required changes and achieving the common target. 
Furthermore, the teams requested benchmarking data as they received on 
formulary compliance in the formulary implementation teams. 
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9.3.3 Systems approach of a hospital viewed as a system 
As a result of the successful implementation and ongoing application of the 
integrated system, the systems approach of a hospital viewed as a system has 
been more and more accepted by different departments and further applications 
explored. 
In July 2004, a new customer service initiative was launched across the 
organisation that centred on the concept of the hospital as a system. I played a 
key role in the design and development of this initiative which aims to ensure a 
positive patient experience throughout the hospital value chain. Importantly the 
launch of the customer service initiative has drawn from the attitudes and new 
'mental models' of staff and management resulting from the success of the 
integrated system. 
As with the examples in sections 9.3.1 and 9.3.2, a number of the concepts in this 
initiative have been derived from the integrated system developed in this study. 
Examples include, the collaborative team approach, the development of group and 
individual measurement and management tools and capability development of 
staff. An extensive process of training in customer service skills has been in 
progress across all hospitals that includes the concept of continuous quality 
improvement. Early results show that the hospital-as-a-system approach has 
resulted in new solutions to long-standing customer complaints. For example, the 
hospital admissions process has been reviewed. Collaborative teams, involving 
mainly the administration and nursing services departments, have worked together 
to develop a more customer friendly process. The process is also more efficient in 
that steps previously duplicated in the administrative and nursing departments are 
now streamlined and only done once. 
An electronic customer satisfaction measurement tool has been developed and 
implemented across all hospitals and benchmark data is collated and distributed 
monthly. The ability to leverage the technology infrastructure, as was done in the 
integrated system, has ensured that all hospitals, large and small have 
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implemented the measurement system. A positive improvement trend is emerging 
both within and across all hospitals in the group, with overall customer satisfaction 
across all hospitals increasing by 4% over 6 months (AHL, 2005). 
Overall, the success and ongoing impact of the implementation of integrated 
system across all hospitals, has resulted in further application and benefits of the 
concepts that were the key innovations of this study. 
9.4 FOCUS AREAS FOR FURTHER RESEARCH 
Ongoing review is an integral part of the integrated system as a result of the inbuilt 
feedback system. The incorporation of the strategic planning systems approach as 
described in Chapter 8 provides a structured approach to respond to external 
factors impacting on the integrated system, and the alignment of the system to the 
overall business strategy. A number of recent changes in the "environment" will 
provide the opportunity for further research. For example, the promulgation of the 
long anticipated pharmaceutical pricing legislation will result in a faster 
acceleration of the shift to risk-based reimbursement tariffs in the private 
healthcare care industry. Further research regarding the impact of this legislation 
on the integrated system will have to be conducted and the relevant changes must 
be implemented. The possible sale of AHL and the threat of the sale of individual 
hospitals could seriously impact the leverage capability, which will require a review 
of the integrated system. The use of the final integrated system, incorporating the 
strategic planning structured process, can be further tested in the above two (2) 
examples. 
In addition, there are a number of other focus areas for further research, which will 
now be described. 
9.4.1 Test the integrated system in other contexts 
This study was a contextual study conducted across a group of private hospitals in 
SA. AHL has been acknowledged as one (1) of the largest private hospital groups 
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outside the U. S. A and has recently entered the U. K healthcare market in 
partnership with a listed company, Care U. K (Dash, 2004: 341). The introduction of 
the integrated system into private healthcare treatment centres in the UK will 
provide the opportunity to test the integrated system in a different country and 
different context. However, these treatment centres are similar in size to small 
hospitals in AHL, and since they are new centres, they have no existing systems 
of management in place. Further research should be conducted to establish 
whether and how the integrated system could be applied in larger hospital 
organisations and organisations with existing management systems for these 
products, such as those found in the USA. 
There is increasing use of private health care systems and organisations by 
national healthcare organisations internationally (Dixon et al., 2004: 223) The 
integrated system has not been tested outside the South African private 
healthcare sector. Its application in the public sector should be explored, starting 
with public-private healthcare partnerships, which are developing in SA. 
9.4.2 Impact on quality of care 
As indicated in the study, the measurement of the impact on quality of care was 
limited to product complaints feedback. Further research should be conducted to 
develop a more rigorous measurement and assessment system regarding the 
impact of the integrated system on quality of care. 
9.4.3 Extension of the integrated system to other areas of healthcare 
The integrated system was applied to acute care hospitals only. Further research 
is required to establish how it can be extended to primary healthcare provision and 
specialised areas such as ambulatory chronic care. 
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9.4.4 Extension of the concepts in the integrated system to other areas 
within AHL 
The systems approach to the development of the integrated system provided a 
new view of the management of pharmaceutical and surgical consumable 
products. Further research should be conducted to explore applications of this 
approach to other areas within AHL. 
9.5 CONCLUSION 
"Engineers say that a new idea has been invented when it is proven to work in a 
laboratory. The idea becomes innovation only when it can be replicated reliably 
on a meaningful scale at practical costs" (Senge, 1990: 5). 
In this study I used action research as the generic research paradigm, because my 
intention was not to only "invent" an integrated system in a "laboratory", but also to 
be able to implement and replicate the invented system across all hospitals in the 
group "at a practical cost". 
As project leader of the business project and the researcher in this study, I 
achieved both the business objectives and objectives of the research study. 
Importantly, as a result of developing and implementing the integrated system, 
including the final progressions of the system, I have set a path of ongoing 
learning, research and possible further innovations in the integrated system for the 
management of pharmaceutical and surgical consumable products across a group 
of hospitals. 
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